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(57) ABSTRACT 
The present invention provides compositions and methods 
for modulating the secretion of transcriptionally regulated 
proteins from recombinant cells. More particularly, the 
present invention provides compositions and methods for 
accelerating the secretion dynamics of human insulin from 
recombinant cells using nonsense mediated mRNA decay of 
the preproinsulin mRNA transcript. 
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COMPOSITIONS AND METHODS FOR THE 
ACCELERATION OF PROTEIN SECRETION 
DYNAMICS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
The present invention claims the priority benefit of U.S. 
Provisional Patent Application Ser. No. 60/374,072, filed on 
Apr. 19, 2002, the entire contents of which are hereby 
incorporated by reference. 
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from the National Science foundation (Award Number EEC-
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BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The field of this invention is techniques to modulate the 
dynamics of transcriptionally regulated protein secretion 
and mRNA stability. These techniques are of particular use 
for improving the dynamics of insulin secretion, which is a 
useful tool in cell-based therapies for insulin-dependent 
diabetes. 
2. Background Art 
Cell-based therapies for treating insulin-dependent diabe-
tes (IDD) can provide a more physiologic regulation of 
blood glucose levels in a less invasive fashion than daily 
insulin injections. Cell sourcing constitutes a critical issue in 
developing a cell-based therapy for treatment of IDD. 
Genetic engineering of non-~ cells, particularly those of 
hepatic origin, for glucose-responsive insulin secretion 
offers significant promise in developing a cell-based therapy 
for insulin-dependent diabetes. Responsiveness to physi-
ologic stimuli is introduced at the gene transcription level by 
using promoters up-regulated by glucose and possibly 
down-regulated by insulin (Thule, et al., 2000 Gene Ther. 
7:205-14; Thule, P. M. & Liu, J. M., 2000 Gene Ther. 
7:1744-52; Lee, et al., 2000 Nature 408:483-8; Barry, et al., 
2001 Hum. Gene Tuer. 12:131-9; Chen, et al., 2001 Mo!. 
Ther. 3:584-90). 
2 
41:1401-9; Dong, H. & Woo, S. L., 2001 Trends Endocrinol. 
Metab. 12:441-6). Although prior reports on the PPI MRNA 
half-life in non-~ cells are limited, data from normal and 
transformed~ cells strongly indicate that the stability of PPI 
5 mRNA is a limiting factor in expediting secretion down-
regulation. In isolated primary rat islets, the half-life of PPI 
mRNA was estimated to be 77 hours under high glucose (17 
mM) and 29 hours under low glucose concentration (3.3 
mM) (Nielsen, et al., 1985, J. Biol. Chem. 260:13585-9). In 
10 ~TC-3 insulinomas, there was only marginal PPI mRNA 
degradation over 24 hours after transcription was stopped 
(Schuppin, G. T. & Rhodes, C. J., 1996, Biochem. J. 
313:259-68), while the half-life of PPI mRNA in RIN-5F 
insulinomas was found to be 58 hours and 26 hours under 
15 high (20 mM) and low (3 mM) glucose concentration, 
respectively (Nielsen, et al., 1985, J. Biol. Chem. 260: 
13585-9). 
The topic of modulation of mRNA stability is currently 
under intense investigation (Guhaniyogi, J. & Brewer, G., 
20 2001, Gene 265:11-23; Clayton, C.E., 2002, Embo. J. 
21:1881-8; van Hoof, A. & Parker, R., 2002, Curr. Biol. 
12:R285-7). Specifically with PPI mRNA, to accelerate the 
rate ofmRNA turnover, the use of anti-sense RNA (Tanigu-
chi, K., et al., 1996, Cell Transplant 5:S55-7) or connecting 
25 the insulin gene with the 3'-untranslated region (3'-UTR) of 
some labile mRNAs, such as those encoding cytokines, have 
been considered (Dong, H. & Woo, S. L., 2001, Trends 
Endocrinol. Metab. 12:441-6). However, these systems 
require the use of more than one construct, or have not 
30 shown to be entirely successful. 
Recently, nonsense-mediated mRNA decay (NMD) has 
received significant attention because of its biological and 
medical importance (Hentze, M. W. & Kulozik, A. E., 1999, 
Cell 96:307-10; Wilusz, C. J., Wang, W. and Peltz, S. W., 
35 2001, Genes Dev. 15:2781-5; Byers, P. H., 2002, J. Clin. 
Invest. 109; 3-6; Maquat, L. E., 2002, Curr. Biol. 12, 
R196-7). Mutant mRNAs with premature stop codons can 
be detected by cells via a surveillance mechanism, and are 
subjected to NMD (Li, S. & Wilkinson, M. F., 1998, 
40 Immunity 8,135-41; Pulak, R. &Anderson, P., 1993, Genes 
Dev. 7, 1885-97). NMD likely evolved in vivo to eliminate 
erratic mRNAs. 
Because of the difficulty in modulating the dynamics of 
protein secretion in general, and insulin secretion specifi-
45 cally, there is a need in the art for techniques to improve the 
efficiency and dynamics of protein secretion from a recom-
binant cell. Based on this concept, glucose-regulated insulin expres-
sion has been achieved in streptozotocin (STZ)-induced 
diabetic rodents (Thule, P. M. & Liu, J.M., 2000 Gene Ther. 
7:1744-52; Lee, et al., 2000 Nature 408:483-8; Barry, et al., 50 
2001 Hum. Gene Tuer. 12:131-9; Chen, et al., 2001 Mo!. 
Ther. 3:584-90). A major advantage of these cells is that they 
are potentially autologous, retrieved as a biopsy from the 
patient. A disadvantage of these cells is that transcriptionally 
controlled cells exhibit sluggish secretion dynamics and thus 55 
may not be suitable, as such, for achieving normoglycemia 
SUMMARY OF THE INVENTION 
It is an object of the present invention to overcome, or at 
least alleviate, one or more of the difficulties or deficiencies 
associated with the prior art. In that regard, the present 
invention provides compositions and methods to improve 
and modulate the dynamics of protein secretion from a 
recombinant cell, generally, and preferably, to modulate the 
in higher diabetic animals and humans. To expedite the 
dynamics of secretion down-regulation, translation needs to 
stop soon after transcription has been turned off. Of particu-
dynamics of insulin secretion from a recombinant cell. The 
methods and compositions provided herein allow for the 
modulation of the dynamics of protein secretion using one 
construct, which greatly simplifies the process of modulat-
ing protein secretion. 
lar significance is the slow dynamics of secretion down- 60 
regulation, which result in the cells secreting insulin long 
after the stimulus has been removed and treatment with 
these cells may thus revert diabetes to hyperinsulinemia and 
hypoglycemia, a serious pathological condition. 
The invention provided herein encompasses a nucleic acid 
producing a nonsense mediated mRNA transcript encoding 
a transcriptionally regulated protein, such as insulin, 
65 wherein the nonsense mediated mRNA transcript has a 
shorter half-life than an mRNA encoding the transcription-
ally regulated protein that is not nonsense mediated. In a 
It has been suggested that the prolonged stability of 
preproinsulin (PPI) mRNA causes the sluggishness of secre-
tion down-regulation (Efrat, S., 1998, Diabetologia 
US 7,250,406 B2 
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preferred embodiment, the nonsense mediated mRNA tran-
script comprises a premature termination signal. Preferably, 
the premature termination signal comprises a stop codon of 
the portion of the mRNA transcript encoding the transcrip-
tionally regulated protein, a polyadenylation sequence and a 
supplementary nucleic acid sequence inserted between the 
stop codon and the polyadenylation sequence. 
4 
calculated using a one-tailed t-test, assuming unequal vari-
ances. Bars indicate standard deviation. 
FIGS. 3A and B show the dynamics of down-regulation of 
insulin gene expression using the Tet-Off system with con-
trol (open circles) and engineered (filled squares) PPI 
mRNA expression. FIG. 3A shows the down-regulation of 
PPI mRNA, while FIG. 3B shows the down-regulation of 
insulin secretion rate. tTA (tetracycline-responsive transcrip-
tional activator, from co-transfected plasmid pTet-Off, a 
The invention provided herein further encompasses a 
mammalian non-~ cell comprising a heterologous nucleic 
acid which produces a nonsense mediated mRNA transcript 
encoding a transcriptionally regulated insulin protein, 
wherein the insulin protein is secreted by the cell and the 
nonsense mediated mRNA transcript has a shorter half-life 
than an mRNA encoding the transcriptionally regulated 
insulin protein that is not nonsense mediated. In a preferred 
embodiment, the non-~ cell is a human hepatic cell. 
10 component of the Tet-Off system) mRNA was used as an 
internal standard for quantitative PPI mRNA assay. In each 
independent test, the PPI mRNA was normalized by desig-
nating the sample without DOX treatment (t=O) as the 
calibrator and setting it at 100%; insulin secretion rates were 
15 normalized by designating the sample with the highest rate 
as the calibrator and setting it at 100%. After an 8-hour 
period of down-regulation, the control and the engineered 
PPI mRNA decreased to 61±8% (P<0.007) and 14±10% 
(P<0.003), respectively, and the insulin secretion rates to 
The invention further provides a method for down-regu-
lating secretion of a transcriptionally regulated protein. In 
one embodiment, the method comprises a) introducing a 
heterologous nucleic acid into a cell, wherein the nucleic 
acid transcribes a nonsense mediated mRNA transcript 
which encodes the transcriptionally regulated protein; and b) 
expressing the heterologous nucleic acid to produce the 
nonsense mediated mRNA transcript encoding the transcrip-
25 tionally regulated protein, such that the protein is secreted by 
the cell and the nonsense mediated mRNA transcript has a 
shorter half-life than an mRNA encoding the transcription-
ally regulated protein that is not nonsense mediated; to 
thereby down-regulate secretion of the protein. The inven-
30 
tion further provides a method of modulating the secretion 
dynamics of insulin by promoting degradation of preproin-
sulin MRNA, comprising introducing a heterologous nucleic 
acid into a non-~ cell, wherein the heterologous nucleic acid 
comprises a preproinsulin-encoding polynucleotide opera-
35 
tively linked to a promoter, and an mRNA transcript tran-
scribed from the heterologous nucleic acid comprises a 
premature termination signal, thereby modulating the secre-
tion dynamics of insulin by promoting degradation of pre-
proinsulin mRNA transcripts. In a preferred embodiment, 
40 
the transciptionally regulated protein is human insulin. In 
one embodiment, the nonsense mediated mRNA transcript 
comprises a premature termination signal, comprising a stop 
codon of the mRNA transcript encoding the transcriptionally 
regulated polypeptide, a polyadenylation sequence and a 
45 
supplementary nucleic acid sequence inserted between the 
stop codon and the polyadenylation sequence. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 provides schematics of the structures of the plas-
mids used for insulin expression. Vectors A, B, C, D and E 
were constructed for evaluating elements that increase insu-
20 75±12% (P<0.05) and 17±7% (P<0.002), respectively. Each 
experiment involved 3 independent tests. Bars indicate 
standard deviations. 
FIG. 4 shows the regulation of insulin secretion from 
transfected HepG2 cells using the Tet-On system with 
control (open circles) and engineered (filled squares) PPI 
mRNA expression. In each independent test, the insulin 
secretion rates were normalized by designating the sample 
with the highest rate as the calibrator and setting it at 100%. 
Each experiment involved 3 independent tests. Bars indicate 
standard deviations. 
FIG. 5 shows the effect of translation on PPI mRNA 
stability (evidence of nonsense-mediated mRNA decay). 
HepG2 hepatomas were transiently co-transfected with 
pTet-Off and the control or engineered PPI mRNA expres-
sion plasmid. tTA mRNA was used as an internal standard 
for quantitative PPI mRNA assay. Cycloheximide was used 
as a translation inhibitor. In each independent test, the PPI 
mRNA ratios (engineered/control) were normalized against 
the sample without cycloheximide treatment (t=O), which 
was set at 100%. Each experiment involved 4 independent 
tests. * and # indicate P values<0.003, and • indicates P 
value=0.36. Bars indicate standard deviations. 
FIG. 6 shows the regulation of insulin secretion from 
transfected HepG2 cells using the Tet-On system with 
control (1-copy) and engineered (2-copy, and 3-copy) PPI 
containing constructs. Transcription was down-regulated by 
removing DOX at time 0. In each independent test, the 
insulin secretion rates were normalized by designating the 
sample with the highest rate as the calibrator and setting it 
50 at 100%. 
lin expression. Vectors F and G are the Tet-responsive 
plasmids with one and three copies, respectively, of PPI 55 
cDNA. 
FIGS. 7 A and 7B show the dynamics of down-regulation 
of insulin gene expression. FIG. 7 A shows the result of using 
the Tet-Off system to evaluate the down-regulation of insulin 
secretion with different copies (1 to 4) of the preproinsulin 
gene. Transcription was down-regulated by adding DOX at 
time 0. FIG. 7B demonstrates the dynamics of insulin 
FIG. 2 demonstrates the systematic increase of insulin 
expression from transfected human HepG2 hepatomas. Cells 
were transiently co-transfected with the test vector shown in 
FIG. 1 (A, B, C, D or E) and the internal control plasmid 
pGL3-control. Luciferase, expressed through pGL3-control, 
was used to normalize the insulin secretion rate and thus 
correct for variations in transfection efficiency. The normal-
ized insulin secretion rate from vector D (highest insulin 
expression vector) was assigned a value of 100. Experiments 
were performed in triplicate wells. *, # and + indicate P 
values<0.02, and • indicates P value<0.04. P values were 
secretion in an impulse test when cells transfected with 
Tet-On system containing 1-4 copies of the preproinsulin 
gene were exposed to a square wave of DOX induction for 
60 1 hour, followed by basal conditions for 7 hours. 
FIG. 8 shows the regulation of insulin secretion from 
transfected HepG2 hepatomas using the Tet-On system 
using constructs containing 1-4 copies of the preproinsulin 
gene. The cells were exposed to cycles of 2 hours of DOX 
65 induction followed by 6 hours at the basal conditions. 
FIGS. 9A and 9B show the dynamics of down-regulation 
of insulin expression using the Tet-Off system, where the 
US 7,250,406 B2 
5 
plasmid contained a preproinsulin-luciferase cDNA con-
struct instead of multiple copies of the preproinsulin gene. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Applicant has demonstrated that nucleic acids producing 
a nonsense mediated mRNA transcript encoding a transcrip-
tionally regulated insulin protein and cells containing these 
nucleic acids result in the improved modulation of protein 
secretion from a recombinant cell compared to nucleic acids 
that do not produce a nonsense mediated mRNA transcript. 
The methods and compositions encompassed by the present 
invention allow for the modulation of the dynamics of 
protein secretion using one construct, which greatly simpli-
fies the process of modulating protein secretion compared to 
other known techniques, such as the use of anti-sense or 
RNA interference technologies. 
The invention provided herein encompasses a nucleic acid 
producing a nonsense mediated mRNA transcript encoding 
a transcriptionally regulated protein, such as insulin, 
wherein the nonsense mediated mRNA transcript has a 
shorter half-life than an mRNA encoding the transcription-
ally regulated protein that is not nonsense mediated. 
The invention provided herein further encompasses a 
mammalian non-~ cell comprising a heterologous nucleic 
acid which produces a nonsense mediated mRNA transcript 
encoding a transcriptionally regulated insulin protein, 
wherein the insulin protein is secreted by the cell and the 
nonsense mediated mRNA transcript has a shorter half-life 
than an mRNA encoding the transcriptionally regulated 
insulin protein that is not nonsense mediated. In a preferred 
embodiment, the non-~ cell is a human hepatic cell. 
The invention further provides a method for down-regu-
lating secretion of a transcriptionally regulated protein. In 
one embodiment, the method comprises a) introducing a 
heterologous nucleic acid into a cell, wherein the nucleic 
acid transcribes a nonsense mediated mRNA transcript 
which encodes the transcriptionally regulated protein; and b) 
expressing the heterologous nucleic acid to produce the 
nonsense mediated mRNA transcript encoding the transcrip-
tionally regulated protein, such that the protein is secreted by 
the cell and the nonsense mediated mRNA transcript has a 
shorter half-life than an mRNA encoding the transcription-
ally regulated protein that is not nonsense mediated; to 
thereby down-regulate secretion of the protein. The inven-
tion further provides a method of modulating the secretion 
dynamics of insulin by promoting degradation of preproin-
sulin mRNA, comprising introducing a heterologous nucleic 
acid into a non-~ cell, wherein the heterologous nucleic acid 
comprises a preproinsulin-encoding polynucleotide opera-
tively linked to a promoter, and an mRNA transcript tran-
scribed from the heterologous nucleic acid comprises a 
premature termination signal, thereby modulating the secre-
tion dynamics of insulin by promoting degradation of pre-
proinsulin mRNA. In a preferred embodiment, the transcip-
tionally regulated protein is human insulin. 
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ordinary skill in the relevant art. In addition to the definitions 
of terms provided below, definitions of common terms in 
molecular biology may also be found in Rieger et al., 1991 
Glossary of genetics: classical and molecular, 5th Ed., 
Berlin: Springer-Verlag; and in Current Protocols in 
Molecular Biology, F. M. Ausubel et al., Eds., Current 
Protocols, a joint venture between Greene Publishing Asso-
ciates, Inc. and John Wiley & Sons, Inc., (1998 Supple-
ment). It is to be understood that as used in the specification 
10 and in the claims, "a" or "an" can mean one or more, 
depending upon the context in which it is used. Thus, for 
example, reference to "a cell" can mean that at least one cell 
can be utilized. 
The present invention may be understood more readily by 
15 reference to the following detailed description of the pre-
ferred embodiments of the invention and the Examples 
included herein. However, before the present compositions 
and methods are disclosed and described, it is to be under-
stood that this invention is not limited to specific nucleic 
20 acids, specific polypeptides, specific cell types, specific host 
cells, specific conditions, or specific methods, etc., as such 
may, of course, vary, and the numerous modifications and 
variations therein will be apparent to those skilled in the art. 
It is also to be understood that the terminology used herein 
25 is for the purpose of describing specific embodiments only 
and is not intended to be limiting. 
The invention provides nucleic acids expressing a non-
sense mediated mRNA transcript encoding a transcription-
ally regulated protein, such as insulin. In a preferred 
30 embodiment, the nucleic acid sequences of the present 
invention are produced by recombinant DNA techniques. 
For example, a nucleic acid molecule encoding the tran-
scriptionally regulated polypeptide is cloned into a vector 
(as described below), the vector is introduced into a host cell 
35 (as described below) and the transcriptionally regulated 
polypeptide is expressed in the host cell or the nucleic acid 
may insert into the genome of the host cell. The transcrip-
tionally regulated polypeptide, or the nucleic acid encoding 
the transcriptionally regulated polypeptide can then be iso-
40 lated from the cells by an appropriate purification scheme 
using standard polypeptide purification techniques. Alter-
nately, the expression levels of the heterologous nucleotide 
can be determined using techniques well known in the art, 
such as by Northern blot. For the purposes of the invention, 
45 the term "recombinant nucleic acid" refers to a polynucle-
otide that has been altered, rearranged or modified by 
genetic engineering. Examples include any cloned poly-
nucleotide, and polynucleotides that are linked or joined to 
heterologous sequences. The term "recombinant" does not 
50 refer to alterations to polynucleotides that result from natu-
rally occurring events, such as spontaneous mutations. 
As used herein, the term "recombinant nucleic acid mol-
ecule" refers to one which is made by the combination of 
two otherwise separated segments of sequence accom-
55 plished by the artificial manipulation of isolated segments of 
polynucleotides by genetic engineering techniques or by 
chemical synthesis. In so doing one may join together 
polynucleotide segments of desired functions to generate a 
desired combination of functions. 
In a preferred embodiment of the above described com-
positions and methods, the nonsense mediated mRNA tran-
script comprises a premature termination signal. Preferably, 60 
the premature termination signal comprises a stop codon of 
the portion of the MRNA transcript encoding the transcrip-
tionally regulated protein, a polyadenylation sequence and a 
supplementary nucleic acid sequence inserted between the 
stop codon and the polyadenylation sequence. 
As also used herein, the term "nucleic acid" and "poly-
nucleotide" refer to RNA or DNA that is linear or branched, 
single or double stranded, or a hybrid thereof. The term also 
encompasses RNA/DNA hybrids. These terms also encom-
pass untranslated sequence located at both the 3' and 5' ends 
65 of the coding region of the gene: at least about 1000 
nucleotides of sequence upstream from the 5' end of the 
coding region and at least about 200 nucleotides of sequence 
Unless otherwise noted, the terms used herein are to be 
understood according to conventional usage by those of 
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downstream from the 3' end of the coding region of the gene. 
Less common bases, such as inosine, 5-methylcytosine, 
6-methyladenine, hypoxanthine and others can also be used 
for antisense, dsRNA and ribozyme pairing. For example, 
polynucleotides that contain C-5 propyne analogues of uri-
dine and cytidine have been shown to bind RNA with high 
affinity and to be potent antisense inhibitors of gene expres-
sion. Other modifications, such as modification to the phos-
phodiester backbone, or the 2'-hydroxy in the ribose sugar 
group of the RNA can also be made. The antisense poly-
nucleotides and ribozymes can consist entirely of ribonucle-
otides, or can contain mixed ribonucleotides and deoxyri-
bonucleotides. The polynucleotides of the invention may be 
produced by any means, including genomic preparations, 
cDNA preparations, in vitro synthesis, RT-PCR, and in vitro 
or in vivo transcription. 
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(e.g., further separating by excising a single band from a 
heterogeneous band population in an agarose gel or nylon 
blot). 
A nucleic acid molecule of the present invention can be 
isolated using standard molecular biology techniques and 
the sequence information provided herein. For example, a 
nucleic acid molecule encoding a mammalian preproinsulin 
can be isolated by the polymerase chain reaction using 
oligonucleotide primers designed based upon a known pre-
10 proinsulin sequence. For example, MRNA can be isolated 
from a mammalian cell and cDNA can be prepared using 
reverse transcriptase (e.g., Moloney MLV reverse tran-
scriptase, available from Gibco/BRL, Bethesda, Md.; or 
AMY reverse transcriptase, available from Seikagaku 
15 America, Inc., St. Petersburg, Fla.). Synthetic oligonucle-
otide primers for polymerase chain reaction amplification 
can be designed based upon the nucleotide sequence. A 
nucleic acid molecule of the invention can be amplified 
using cDNA or, alternatively, genomic DNA, as a template 
In a preferred embodiment, the nucleic acid of the present 
invention is a heterologous nucleic acid encoding a tran-
scriptionally regulated protein. As used herein, the term 
"heterologous nucleic acid" refers to a nucleic acid that has 
been isolated and is introduced into a host cell using any 
known or later developed recombinant DNA technique 
known to those of ordinary skill in the art. An "isolated" 
nucleic acid molecule is one that is substantially separated 
from other nucleic acid molecules that are present in the 
natural source of the nucleic acid (i.e., sequences encoding 
other polypeptides). Preferably, an "isolated" nucleic acid is 
free of some of the sequences which naturally flank the 
nucleic acid (i.e., sequences located at the 5' and 3' ends of 30 
the nucleic acid) in its naturally occurring replicon. For 
example, a cloned nucleic acid is considered isolated, as is 
20 and appropriate oligonucleotide primers according to stan-
dard PCR amplification techniques. The nucleic acid mol-
ecule so amplified can be cloned into an appropriate vector 
and characterized by DNA sequence analysis. Furthermore, 
oligonucleotides corresponding to a nucleotide sequence of 
25 interest can be prepared by standard synthetic techniques, 
e.g., using an automated DNA synthesizer. These cDNAs 
may comprise sequences encoding the nucleic acid of inter-
est, (i.e., the "coding region" of preproinsulin), as well as 5' 
untranslated sequences and 3' untranslated sequences. 
In one embodiment of the present invention, the heter-
ologous nucleic acid comprises a nucleic acid sequence 
encoding an intron as defined in SEQ ID NO: 1, connected 
to a nucleic acid sequence encoding a mutated preproinsulin 
as defined in SEQ ID N0:2. In a further preferred embodi-
a cDNA molecule. In various embodiments, the isolated 
transcriptionally regulated polypeptide or nucleotide 
sequence encoding the transcriptionally regulated polypep-
tide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 
0.5 kb, or 0.1 kb of nucleotide sequences which naturally 
flank the nucleic acid molecule in genomic DNA of the cell 
from which the nucleic acid is derived (e.g., a mammalian, 
or a human cell). A nucleic acid is also considered isolated 
if it has been altered by human intervention, or placed in a 
locus or location that is not its natural site, or if it is 
introduced into a cell by transfection. Moreover, an "iso-
lated" nucleic acid molecule can be free from some of the 
other cellular material with which it is naturally associated, 
or culture medium when produced by recombinant tech-
niques, or chemical precursors or other chemicals when 
chemically synthesized. 
Specifically excluded from the definition of "isolated 
nucleic acids" are: naturally-occurring chromosomes (such 
as chromosome spreads), artificial chromosome libraries, 
genomic libraries, and cDNA libraries that exist either as an 
in vitro nucleic acid preparation or as a transfected/trans-
formed host cell preparation, wherein the host cells are 
either an in vitro heterogeneous preparation or plated as a 
heterogeneous population of single colonies. Also specifi-
cally excluded are the above libraries wherein a specified 
nucleic acid makes up less than 5% of the number of nucleic 
acid inserts in the vector molecules. Further specifically 
excluded are whole cell genomic DNA or whole cell RNA 
preparations (including whole cell preparations that are 
mechanically sheared or enzymatically digested). Even fur-
ther specifically excluded are the whole cell preparations 
found as either an in vitro preparation or as a heterogeneous 
mixture separated by electrophoresis wherein the nucleic 
acid of the invention has not further been separated from the 
heterologous nucleic acids in the electrophoresis medium 
35 ment, the heterologous nucleic acid comprises a nucleic acid 
sequence as defined in SEQ ID NO: 1, connected to a nucleic 
acid sequence encoding three copies of the mutated PPI as 
defined in SEQ ID N0:3. The nucleic acid sequence as 
defined in SEQ ID NO:l, connected to a nucleic acid 
40 sequence as defined in SEQ ID N0:3, is defined in SEQ ID 
N0:4. In other embodiments, the heterologous nucleic acid 
sequence comprises SEQ ID N0:3, optionally linked to an 
intron. The intron can be located upstream or downstream of 
the nucleic acid sequence. In other embodiments the heter-
45 ologous nucleic acid comprises a nucleic acid sequence that 
encodes a polypeptide as defined in SEQ ID N0:5, or 
orthologs or homologs thereof. In other embodiments, the 
heterologous nucleic acid comprises a nucleic acid sequence 
that encodes wild-type insulin. In another embodiment, the 
50 heterologous nucleic acid comprises a plurality of copies of 
the human preproinsulin gene. In still another embodiment, 
the heterologous nucleic acid comprises one or more copies 
of the human preproinsulin gene. Preferably, if the heter-
ologous nucleic acid comprises one copy of the human 
55 preproinsulin gene, it additionally comprises a premature 
termination signal comprising a supplementary nucleic acid 
sequence inserted after the stop codon of the preproinsulin 
gene and inserted before the sequence signaling for the 
addition of the poly-A tail. In another embodiment, the 
60 heterologous nucleic acid comprises one copy of the human 
preproinsulin gene and comprises a plurality of copies of a 
nucleic acid sequence that has greater than 90% homology 
to the human preproinsulin gene. It is to be understood that 
while the furin mutated preproinsulin gene was used in the 
65 examples described herein, the use of a wild-type prepro-
insulin gene and homologs and orthologs thereof is also 
encompassed by the present invention. 
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As used herein, a "gene" is the fundamental physical and 
functional unit of heredity. In biochemical terms, a gene is 
an ordered sequence of nucleotides located in a particular 
position on a particular chromosome that encodes a specific 
functional product (i.e., a protein or RNA molecule). As 
used herein, a gene is composed not only of coding 
sequences but can comprise adjacent DNA regions involved 
in control of the transcription of the coding sequences (e.g., 
promoters, enhancers) and intrans. 
The heterologous nucleic acid of the present invention 
transcribes a nonsense mediated mRNA transcript which 
encodes a transcriptionally regulated protein. As used 
herein, a "nonsense mediated mRNA transcript" refers to a 
mRNA transcript that has a shorter half-life than an mRNA 
transcript that is not nonsense mediated. Methods to deter-
mine the half-life of an mRNA transcript or a population of 
mRNA transcripts are well known to those of ordinary skill 
in the art. The half-life of a nonsense mediated mRNA 
transcript is shorter due to nonsense mediated mRNA decay. 
As used herein, the term "nonsense mediated mRNA decay" 
refers to a surveillance mechanism in a cell that serves to 
eliminate mRNA transcripts that have premature termination 
codons or otherwise have an abnormal length of nucleotide 
sequence between the termination codon and the polyade-
nylation signal (for review, see Hentze & Kulozik, 1999 Cell 
96:307-310; Byers, 2002 J. Clin. Invest. 109:3-6; Maquat, 
2002 Curr. Biol. 12(6):R196-7). As used herein, the term 
"abnormal length" refers to a length of nucleotide sequences 
that is not naturally found interposed between the termina-
tion codon and the polyadenylation signal. 
In a preferred embodiment of the present invention, 
nonsense mediated mRNA decay is induced by the presence 
of a premature termination signal in the mRNA transcript 
that encodes for a transcriptionally regulated protein. Pref-
erably, the premature termination signal comprises a stop 
codon of the portion of the mRNA transcript encoding the 
transcriptionally regulated protein, a polyadenylation 
sequence and a supplementary nucleic acid sequence 
inserted between the stop codon and the polyadenylation 
sequence. As used herein, the term "premature termination 
signal" refers to a combination of sequences that serves to 
indicate to the cell that the resultant protein will be trun-
cated, and serves to induce nonsense mediated mRNA 
decay. The use of the term "premature" in this sense does not 
necessarily indicate that the stop codon of the portion of the 
mRNA transcript encoding the transcriptionally regulated 
protein has been changed or moved upstream; it merely 
indicates that the surveillance mechanism of a cell perceives 
that the stop codon is in a premature position. 
In a preferred embodiment, the surveillance mechanism 
of the cell perceives that the stop codon of the portion of the 
mRNA transcript that encodes for the transcriptionally regu-
lated protein is premature due to the presence of a supple-
mentary nucleic acid that has been inserted between the stop 
codon and the sequence signaling for cleavage of the mRNA 
and the addition of a poly A sequence. As used herein, the 
term "supplementary nucleic acid" refers to the addition of 
nucleic acid sequences that are not naturally located imme-
diately upstream of the poly-A sequence. In one embodi-
ment, the supplementary nucleic acid sequence is one or 
more copies of the preproinsulin gene. In another embodi-
ment, the supplementary nucleic acid comprises a gene 
encoding a transcriptionally regulated protein. In another 
embodiment, the supplementary nucleic acid is a coding 
region of a gene. In another embodiment, the supplementary 
nucleic acid is a cDNA sequence that encodes for a protein. 
In still other embodiments, the supplementary nucleic acid 
10 
is non-coding. Specifically excluded from the definition of a 
"supplementary nucleic acid" are AU-rich elements from the 
3' UTR of a highly labile mRNA, such as from a cytokine, 
IGFBP-1, and proto-oncogenes. 
In preferred embodiments of the present invention, the 
supplementary nucleic acid comprises a nucleic acid 
sequence of approximately 50-3000 bp, more preferably, of 
between approximately 200-2500 bp, and still more prefer-
ably of between approximately 350-1650 bp. In a preferred 
10 embodiment, the supplementary nucleic acid comprises a 
nucleic acid sequence of approximately 600-1050 bp, more 
preferably comprises a nucleic acid sequence of approxi-
mately 600-800 bp, and more preferably comprises a nucleic 
acid sequence of approximately 700 bp in length. In other 
15 embodiments of the present invention, the stop codon of the 
portion of the mRNA transcript encoding the transcription-
ally regulated protein is located approximately 50-3000 
nucleotides upstream of the polyadenylation sequence, more 
preferably approximately 200-2500 nucleotides upstream of 
20 the polyadenylation sequence, more preferably approxi-
mately 350-1650 nucleotides upstream of the polyadenyla-
tion sequence, more preferably approximately 600-1050 
nucleotides upstream of the polyadenylation sequence, more 
preferably approximately 600-800 nucleotides upstream of 
25 the polyadenylation sequence, and still more preferably 
approximately 700 nucleotides upstream of the polyadeny-
lation sequence. 
The nucleic acids of the present invention encode for a 
transcriptionally regulated protein. As used herein, the term 
30 "protein" is synonymous with the term "polypeptide." As 
used herein, the term "polypeptide" refers to a chain of at 
least four amino acids joined by peptide bonds. The chain 
may be linear, branched, circular or combinations thereof. 
As used herein, a "transcriptionally regulated protein" refers 
35 to a protein whose production is regulated at the level of 
transcription, or the production of mRNA. Transcriptional 
regulation is controlled by transcriptional response elements 
such as promoters, enhancers, or other regulatory elements. 
Any one of many different elements located in a transcrip-
40 tional response element can independently activate or 
repress transcription of a gene. For example, the transcrip-
tion of preproinsulin in ~ cells is activated by glucose and 
down-regulated by insulin. While the compositions and 
methods of the present invention encompass all transcrip-
45 tionally regulated proteins, in a preferred embodiment of the 
present invention, the transcriptionally regulated protein is 
insulin. More preferably, the transcriptionally regulated pro-
tein is human insulin. 
The invention also provides chimeric or fusion polypep-
50 tides. As used herein, a "chimeric polypeptide" or "fusion 
polypeptide" comprises a nucleotide sequence encoding a 
transcriptionally regulated protein operatively linked to a 
nucleotide sequence that does not encode a transcriptionally 
regulated protein, or that is linked to a nucleic acid sequence 
55 that encodes a different transcriptionally regulated protein. 
As used herein with respect to the fusion polypeptide, the 
term "operatively linked" is intended to indicate that the 
nucleotide sequence encoding a transcriptionally regulated 
protein and the nucleotide sequence it is linked to are fused 
60 to each other so that both sequences fulfill the proposed 
function attributed to the sequence used. The nucleotide 
sequence not encoding a transcriptionally regulated protein 
or encoding a different protein can be fused to the N-termi-
nus or C-terminus of the nucleotide sequence encoding a 
65 transcriptionally regulated protein. For example, in one 
embodiment, the fusion polypeptide is a GST-transcription-
ally regulated protein fusion polypeptide in which the tran-
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scriptionally regulated protein sequences are fused to the 
C-terminus of the GST sequences. Such fusion polypeptides 
can facilitate the purification of recombinant transcription-
ally regulated proteins. In another embodiment, the fusion 
polypeptide is a transcriptionally regulated protein contain-
ing a heterologous signal sequence at its N-terminus. In 
certain host cells (e.g., mammalian host cells), expression 
and/or secretion of a transcriptionally regulated protein can 
be increased through use of a heterologous signal sequence. 
In another embodiment, the fusion polypeptide is a tran- 10 
scriptionally regulated protein operatively linked to a 
nucleic acid encoding a detectable signal peptide, such as, 
but not limited to, luciferase. 
Preferably, a transcriptionally regulated chimeric or 
fusion polypeptide of the invention is produced by standard 15 
recombinant DNA techniques. For example, DNA fragments 
coding for the different polypeptide sequences are ligated 
together in-frame in accordance with conventional tech-
niques, for example by employing blunt-ended or stagger-
ended termini for ligation, restriction enzyme digestion to 20 
provide for appropriate termini, filling-in of cohesive ends 
as appropriate, alkaline phosphatase treatment to avoid 
undesirable joining and enzymatic ligation. In another 
embodiment, the fusion gene can be synthesized by con-
ventional techniques including automated DNA synthesiz- 25 
ers. Alternatively, PCR amplification of gene fragments can 
be carried out using anchor primers which give rise to 
complementary overhangs between two consecutive gene 
fragments which can subsequently be annealed and re-
amplified to generate a chimeric gene sequence (See, e.g., 30 
Current Protocols in Molecular Biology, Eds. Ausubel et al. 
John Wiley & Sons: 1992). Moreover, many expression 
vectors are commercially available that already encode a 
fusion moiety (e.g., a GST polypeptide). An isolated nucle-
otide encoding a transcriptionally regulated protein can be 35 
cloned into such an expression vector such that the fusion 
moiety is linked in-frame to the nucleotide. 
Large amounts of the recombinant DNA molecules may 
be produced by replication in a suitable host cell. Natural or 
synthetic DNA fragments coding for a protein of interest are 40 
incorporated into recombinant polynucleotide constructs, 
typically DNA constructs, capable of introduction into and 
replication in a prokaryotic or eukaryotic cell, especially 
Escherichia coli or Saccharomyces cerevisiae. Commonly 
used prokaryotic hosts include strains of Escherichia coli, 45 
although other prokaryotes, such as Bacillus subtilis or a 
pseudomonad, may also be used. Eukaryotic host cells 
include yeast, filamentous fungi, animal, plant, insect, 
amphibian and avian species. Such factors as ease of 
manipulation, ability to appropriately glycosylate expressed 50 
proteins, degree and control of protein expression, ease of 
purification of expressed proteins away from cellular con-
taminants or other factors influence the choice of the host 
cell. 
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ated mRNA transcript which is translated into a transcrip-
tionally regulated protein. The cells comprising the nucleic 
acids of the invention have improved control over the 
modulation of the dynamics of protein secretion. As used 
herein, the term "modulating protein secretion" is used 
interchangeably with the term "modulating secretion 
dynamics," and refers to a statistically significant effect on 
the levels of protein secretion due to the introduction of the 
heterologous nucleic acid transcribing a nonsense mediated 
mRNA transcript in comparison to the levels of protein 
secretion upon introduction of a heterologous nucleic acid 
that does not transcribe a nonsense mediated mRNA tran-
script. In a preferred embodiment, the introduction of the 
heterologous nucleic acid of the invention leads to a faster 
down-regulation of the secretion of the protein of interest. 
Preferably, the acceleration of the down-regulation of the 
secretion of the protein is due to increased degradation of the 
mRNA transcript encoding the transcriptionally regulated 
protein due to nonsense mediated mRNA decay. Methods to 
determine levels of protein secretion are well known to those 
of ordinary skill in the art. 
In addition to fragments and fusion polypeptides of the 
transcriptionally regulated proteins described herein, the 
present invention includes homologs and analogs of natu-
rally occurring transcriptionally regulated proteins and 
nucleotides encoding transcriptionally regulated proteins, 
and of naturally occurring nucleotides encoding a transcrip-
tionally regulated protein. "Homo logs" are defined herein as 
two nucleic acids or polypeptides that have similar, or 
substantially identical, nucleotide or amino acid sequences, 
respectively. Homologs include allelic variants, orthologs, 
paralogs, agonists and antagonists of transcriptionally regu-
lated proteins as defined hereafter. The term "homolog" 
further encompasses nucleic acid molecules that differ due 
to degeneracy of the genetic code and thus encode the same 
transcriptionally regulated protein molecule. As used herein 
a "naturally occurring" transcriptionally regulated protein 
refers to a transcriptionally regulated protein amino acid 
sequence that occurs in nature. Similarly, a "naturally occur-
ring" isolated nucleotide encoding a transcriptionally regu-
lated protein refers to a nucleic acid sequence that occurs in 
nature. 
Nucleic acid molecules corresponding to natural allelic 
variants and analogs, orthologs and paralogs of a transcrip-
tionally regulated protein or isolated nucleotide encoding a 
transcriptionally regulated protein can be isolated using a 
hybridization probe according to standard hybridization 
techniques under stringent or moderate hybridization con-
ditions. In an alternative embodiment, homologs can be 
identified by screening combinatorial libraries of mutants, 
for agonist or antagonist activity. There are a variety of 
methods that can be used to produce libraries of potential 
transcriptionally regulated protein homologs from a degen-
erate oligonucleotide sequence. Chemical synthesis of a 
As used herein, "recombinant host cells" are those which 
have been genetically modified to contain an isolated or 
other recombinant DNA molecule, as described herein. The 
DNA can be introduced by any means known to the art 
which is appropriate for the particular type of cell, including 
without limitation, transformation with plasmids, including 
different methods of plasmid delivery such as, without 
limitation, liposomal delivery, electroporation, or naked 
plasmid injection; transduction with viral vectors; or DNA 
delivery mediated by polymeric agents. 
55 degenerate gene sequence can be performed in an automatic 
DNA synthesizer, and the synthetic gene is then ligated into 
an appropriate expression vector. Use of a degenerate set of 
genes allows for the provision, in one mixture, of all of the 
sequences encoding the desired set of potential transcrip-
60 tionally regulated protein sequences. Methods for synthe-
sizing degenerate oligonucleotides are known in the art. See, 
e.g., Narang, S. A., 1983, Tetrahedron 39:3; Itakura et al., 
1984, Annu. Rev. Biochem. 53:323; Itakura et al., 1984, 
The present invention provides for cells and methods for 65 
obtaining cells that contain the nucleic acids of the inven-
tion, wherein the nucleic acid transcribes a nonsense medi-
Science 198:1056; Ike eta!., 1983,NucleicAcidRes. 11:477. 
In addition, libraries of fragments of the transcriptionally 
regulated protein coding regions can be used to generate a 
variegated population of transcriptionally regulated protein 
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fragments for screening and subsequent selection of 
homologs of a transcriptionally regulated protein. In one 
embodiment, a library of coding sequence fragments can be 
generated by treating a double stranded PCR fragment of a 
transcriptionally regulated protein coding sequence with a 
nuclease under conditions wherein nicking occurs only 
about once per molecule, denaturing the double stranded 
DNA, renaturing the DNA to form double stranded DNA, 
which can include sense/antisense pairs from different 
nicked products, removing single stranded portions from 10 
reformed duplexes by treatment with Sl nuclease, and 
ligating the resulting fragment library into an expression 
vector. By this method, an expression library can be derived 
which encodes N-terminal, C-terminal, and internal frag-
ments of various sizes of the transcriptionally regulated 15 
protein. 
Several techniques are known in the art for screening gene 
products of combinatorial libraries made by point mutations 
or truncation, and for screening cDNA libraries for gene 
products having a selected property. Such techniques are 20 
adaptable for rapid screening of the gene libraries generated 
by the combinatorial mutagenesis of transcriptionally regu-
lated protein homologs. The most widely used techniques, 
which are amenable to high through-put analysis, for screen-
ing large gene libraries typically include cloning the gene 25 
library into replicable expression vectors, transforming 
appropriate cells with the resulting library of vectors, and 
expressing the combinatorial genes under conditions in 
which detection of a desired activity facilitates isolation of 
the vector encoding the gene whose product was detected. 30 
Recursive ensemble mutagenesis (REM), a new technique 
that enhances the frequency of functional mutants in the 
libraries, can be used in combination with the screening 
assays to identify transcriptionally regulated protein 
homologs (Arkin & Yourvan, 1992, PNAS 89:7811-7815; 35 
Delgrave et al., 1993, Polypeptide Engineering 6(3):327-
331). 
As stated above, the present invention includes transcrip-
tionally regulated proteins, nucleic acids encoding transcrip-
tionally regulated proteins and homologs and analogs 40 
thereof. To determine the percent sequence identity of two 
amino acid sequences, the sequences are aligned for optimal 
comparison purposes (e.g., gaps can be introduced in the 
sequence of one polypeptide for optimal alignment with the 
other polypeptide or nucleic acid). The amino acid residues 45 
at corresponding amino acid positions are then compared. 
When a position in one sequence is occupied by the same 
amino acid residue as the corresponding position in the other 
sequence, then the molecules are identical at that position. 
The same type of comparison can be made between two 50 
nucleic acid sequences. 
The percent sequence identity between the two sequences 
is a function of the number of identical positions shared by 
the sequences (i.e., percent sequence identity=numbers of 
identical positions/total numbers of positionsxl 00). Prefer- 55 
ably, the isolated amino acid homologs included in the 
present invention are at least about 25-30%, preferably at 
least 30-40%, and more preferably at least about 40-50%, 
50-60%, 60-70%, 70-75%, 75-80%, 80-85%, 85-90% or 
90-95%, and most preferably at least about 96%, 97%, 98%, 60 
99% or more identical to an entire amino acid sequence. In 
yet another embodiment, the isolated amino acid homologs 
included in the present invention are at least about 25-30%, 
preferably at least 40-50%, and more preferably at least 
about 50-60%, 60-70%, 70-75%,75-80%,80-85%, 85-90% 65 
or 90-95%, and most preferably at least about 96%,97%, 
98%, 99% or more identical to an entire amino acid 
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sequence encoded by a nucleic acid sequence. In other 
embodiments, the transcriptionally regulated protein amino 
acid homologs have sequence identity over at least 15 
contiguous amino acid residues, more preferably at least 25 
contiguous amino acid residues, and most preferably at least 
35 contiguous amino acid residues. 
For the purposes of the invention, the percent sequence 
identity between two nucleic acid or polypeptide sequences 
may be determined using the "Blast Two Sequences" pro-
gram available at National Center for Biotechnology Infor-
mation (http://www.ncbi.nlm.nih.gov/blast/bl2seq/ 
bl2.html). The percent sequence identity of two nucleic 
acids is determined using the algorithm of Karlin & Alts-
chul, 1990 Proc. Natl. Acad. Sci. USA 87:2264-2268, modi-
fied as in Karlin & Altschul, 1993 Proc. Natl. Acad. Sci. 
USA 90:5873-5877. Such an algorithm is incorporated into 
the NBLAST and XBLAST programs of Altschul et al., 
1990 J. Mo!. Biol. 215:402-410. BLAST nucleotide searches 
are performed with the NBLAST program, score=lOO, 
wordlength=12, to obtain nucleotide sequences with the 
desired percent sequence identity. To obtain gapped align-
ments for comparison purposes, Gapped BLAST is used as 
described inAltschul et al., 1997 Nucl. Acids. Res. 25:3389-
3402. When utilizing BLAST and Gapped BLAST pro-
grams, the default parameters of the respective programs 
(NBLAST and XBLAST) are used. See http://www.ncbi.ni-
h.gov/. It is to be understood that for the purposes of 
determining sequence identity when comparing a DNA 
sequence to an RNA sequence, a thymidine nucleotide is 
equivalent to a uracil nucleotide. 
Hybridization procedures are useful for identifying poly-
nucleotides with sufficient homology to the subject regula-
tory sequences to be useful as taught herein. The particular 
hybridization technique is not essential to the subject inven-
tion. As improvements are made in hybridization techniques, 
they can be readily applied by one of ordinary skill in the art. 
A probe and sample are combined in a hybridization 
buffer solution and held at an appropriate temperature until 
annealing occurs. Thereafter, the membrane is washed free 
of extraneous materials, leaving the sample and bound probe 
molecules typically detected and quantified by autoradiog-
raphy and/or liquid scintillation counting. As is well known 
in the art, if the probe molecule and nucleic acid sample 
hybridize by forming a strong non-covalent bond between 
the two molecules, it can be reasonably assumed that the 
probe and sample are essentially identical, or completely 
complementary if the annealing and washing steps are 
carried out under conditions of high stringency. The probe's 
detectable label provides a means for determining whether 
hybridization has occurred. 
Various degrees of stringency of hybridization can be 
employed for studies of cloned sequences isolated as 
described herein. The more stringent the conditions, the 
greater the complementarity that is required for duplex 
formation. Stringency can be controlled by temperature, 
probe concentration, probe length, ionic strength, time, and 
the like. Preferably, hybridization is conducted under mod-
erate to high stringency conditions by techniques well 
known in the art, as described, for example in Keller, G. H., 
M. M. Manak, 1987 DNA Probes, Stockton Press, New 
York, N.Y., pp. 169-170, hereby incorporated by reference. 
In a preferred embodiment, the hybridization is selective for 
target DNA. As used herein, the term "selective hybridiza-
tion" or "selectively hybridizing" refers to the ability to 
discern between the binding of a nucleic acid sequence to a 
target DNA sequence as compared to other non-target DNA 
sequences. 
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As used herein, moderate to high stringency conditions 
for hybridization are conditions that achieve the same, or 
about the same, degree of specificity of hybridization as the 
conditions described herein. As used herein, the term 
"highly stringent" or "high stringency conditions" com-
prises hybridizing at 68° C. in 5x SSC/5x Denhardt's 
solution/0.1 % SDS, and washing in 0.2x SSC/0.1 % SDS at 
65° C. As used herein, the term "moderately stringent" or 
"moderate stringency conditions" comprise hybridizing at 
55° C. in 5x SSC/5x Denhardt's solution/0.1 % SDS and 10 
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determined by the following formula: TM(° C.)=2(number 
TIA base pairs+4(number G/C base pairs) (Suggs et al., 1981 
!CB-UCLA Symp. Dev. Biol. Using Purified Genes, D. D. 
Brown (Ed.), Academic Press, New York, 23:683-693). 
Washes are typically carried out as follows: twice at room 
temperature for 15 minutes 1 xSSPE, 0.1 % SDS (low strin-
gency wash), and once at the hybridization temperature for 
15 minutes in lxSSPE, 0.1 % SDS (moderate stringency 
wash). 
In general, salt and/or temperature can be altered to 
change stringency. With a labeled DNA fragment> 70 or so 
bases in length, the following conditions can be used: Low, 
1 or 2x SSPE, room temperature; Low, 1or2xSSPE, 42° C.; 
washing at 42° C. in 3x SSC. The parameters of temperature 
and salt concentration can be varied to achieve the desired 
level of sequence identity between probe and target nucleic 
acid. See, e.g., Sambrook et al. 1989 Molecular Cloning, 
Second Edition, Cold Spring Harbor Laboratory, Plainview, 
N.Y. Ausubel et al., 1995 Current Protocols in Molecular 
Biology, John Wiley & Sons, NY, N.Y., Meinkoth and Wahl, 
1984, Anal. Biochem. 138:267-284; or Tijssen, 1993, Labo-
ratory Techniques in Biochemistry and Molecular Biology: 
15 Moderate, 0.5x or lxSSPE, 60° C.; and High, O.lxSSPE, 
65° C. 
Hybridization with Nucleic Acid Probes, Part I, Chapter 2, 20 
Elsevier, N.Y., for further guidance on hybridization condi-
tions. 
Specifically, hybridization of immobilized DNA in South-
ern blots with 32P-labeled gene specific probes is performed 
One subset of these homologs are allelic variants. As used 
herein, the term "allelic variant" refers to a nucleotide 
sequence containing polymorphisms that lead to changes in 
the amino acid sequences of a transcriptionally regulated 
protein and that exist within a natural population. Such 
natural allelic variations can typically result in 1-5% vari-
ance in a transcriptionally regulated protein or isolated 
nucleotide encoding a transcriptionally regulated protein. 
Allelic variants can be identified by sequencing the nucleic 
acid sequence of interest in a number of different plants, or 
other organisms, which can be readily carried out by using 
hybridization probes to identify the same transcriptionally 
regulated protein or isolated nucleotide encoding a transcrip-
tionally regulated protein genetic locus in those organisms. 
Any and all such nucleic acid variations and resulting amino 
acid polymorphisms or variations in a transcriptionally 
regulated protein or isolated nucleotide encoding a transcrip-
tionally regulated protein that are the result of natural allelic 
variation and that do not alter the functional activity of a 
transcriptionally regulated protein or isolated nucleotide 
encoding a transcriptionally regulated protein, are intended 
to be within the scope of the invention. 
Moreover, nucleic acid molecules encoding transcription-
ally regulated proteins from the same or other species such 
as analogs, orthologs, and paralogs, are intended to be within 
the scope of the present invention. As used herein, the term 
"analogs" refers to two nucleic acid sequences that have the 
by standard methods (Maniatis et al., 1982 Molecular Clan- 25 
ing, Cold Spring Harbor Laboratory, Plainview, N.Y.). As 
used herein, a "probe" is typically attached to a label or 
reporter molecule and is used to identify and isolate other 
sequences of interest. Probes comprising synthetic oligo-
nucleotides or other polynucleotides may be derived from 30 
naturally occurring or recombinant single or double stranded 
nucleic acids or be chemically synthesized. Polynucleotide 
probes may be labeled by any of the methods known in the 
art, e.g., random hexamer labeling, nick translation, or the 
Kienow fill-in reaction. e.g., by the phosphoramidite method 35 
described by Beaucage & Caruthers, 1981 Tetra. Letts. 22: 
1859-1862 or the triester method according to Matteuci et 
al., 1981 J. Am. Chem. Soc., 103: 3185, and may be 
performed on commercial automated oligonucleotide syn-
thesizers. A double-stranded fragment may be obtained from 40 
the single stranded product of chemical synthesis either by 
synthesizing the complementary strand and annealing the 
strand together under appropriate conditions or by adding 
the complementary strand using DNA polymerase with an 
appropriate primer sequence. 45 same or similar function, but that have evolved separately in 
unrelated organisms. As used herein, the term "orthologs" 
refers to two nucleic acids from different species, but that 
have evolved from a common ancestral gene by speciation. 
In general, hybridization and subsequent washes are car-
ried out under moderate to high stringency conditions that 
allowed for detection of target sequences with homology to 
a particular nucleic acid molecule of interest. For double-
stranded DNA gene probes, hybridization can be carried out 50 
overnight at 20-25° C. below the melting temperature (Tm) 
Normally, orthologs encode polypeptides having the same or 
similar functions. As also used herein, the term "paralogs" 
refers to two nucleic acids that are related by duplication 
of the DNA hybrid in 6xSSPE 5xDenhardt's solution, 0.1 % 
SDS, 0.1 mg/ml denatured DNA. The melting temperature is 
described by the following formula (Beltz et al., 1983 
Methods of Enzymology, R. Wu, L, Grossman and K Mo!- 55 
dave (Eds.) Academic Press, New York 100:266-285). 
within a genome. Paralogs usually have different functions, 
but these functions may be related (Tatusov, R. L. et al., 
1997, Science 278(5338):631-637). Analogs, orthologs and 
paralogs of a naturally occurring transcriptionally regulated 
protein can differ from the naturally occurring transcription-
Tm~Sl.5° C.+16.6 Log[Na•]+0.41(+G+C)-0.61(% 
formamide)-600/length of duplex in base pairs. 
Washes are typically carried out as follows: twice at room 
temperature for 15 minutes in 1 xSSPE, 0.1 % SDS (low 
stringency wash), and once at TM-20° C. for 15 minutes in 
0.2xSSPE, 0.1% SDS (moderate stringency wash). 
For oligonucleotide probes, hybridization is carried out 
overnight at 10-20° C. below the melting temperature (Tm) 
of the hybrid 6x SSPE, 5x Denhardt's solution, 0.1 % SDS, 
0.1 mg/ml denatured DNA. Tm for oligonucleotide probes is 
ally regulated protein by post-translational modifications, by 
amino acid sequence differences, or by both. Post-transla-
tional modifications include in vivo and in vitro chemical 
60 derivatization of polypeptides, e.g., acetylation, carboxyla-
tion, phosphorylation, or glycosylation, and such modifica-
tions may occur during polypeptide synthesis or processing 
or following treatment with isolated modifying enzymes. In 
particular, orthologs of the invention will generally exhibit 
65 at least 80-85%, more preferably, 85-90% or 90-95%, and 
most preferably 95%, 96%, 97%, 98% or even 99% identity 
or sequence identity with all or part of a naturally occurring 
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transcriptionally regulated protein amino acid sequence and 
will exhibit a function similar to a transcriptionally regulated 
protein. 
In addition to naturally-occurring variants of a transcrip-
tionally regulated protein sequence that may exist in the 
population, the skilled artisan will further appreciate that 
changes can be introduced by mutation into a nucleotide 
sequence, thereby leading to changes in the amino acid 
sequence of the encoded transcriptionally regulated protein, 
without altering the functional activity of the transcription-
ally regulated protein. For example, nucleotide substitutions 
leading to amino acid substitutions at "non-essential" amino 
acid residues can be made in a sequence. A "non-essential" 
amino acid residue is a residue that can be altered from the 
wild-type sequence of one of the transcriptionally regulated 
proteins without altering the activity of said transcriptionally 
regulated protein, whereas an "essential" amino acid residue 
is required for transcriptionally regulated protein activity. 
Other amino acid residues, however, (e.g., those that are not 
conserved or only semi-conserved in the domain having 
transcriptionally regulated protein activity) may not be 
essential for activity and thus are likely to be amenable to 
alteration without altering the activity. 
An isolated nucleic acid molecule encoding a transcrip-
tionally regulated protein can be created by introducing one 
or more nucleotide substitutions, additions or deletions into 
a nucleotide sequence, such that one or more amino acid 
substitutions, additions, or deletions are introduced into the 
encoded polypeptide. Mutations can be introduced into a 
nucleotide sequence by standard techniques, such as site-
directed mutagenesis and PCR-mediated mutagenesis. Pref-
erably, conservative amino acid substitutions are made at 
one or more predicted non-essential amino acid residues. A 
"conservative amino acid substitution" is one in which the 
amino acid residue is replaced with an amino acid residue 
having a similar side chain. 
Families of amino acid residues having similar side chains 
have been defined in the art. These families include amino 
acids with basic side chains (e.g., lysine, arginine, histidine), 
acidic side chains (e.g., aspartic acid, glutamic acid), 
uncharged polar side chains (e.g., glycine, asparagine, 
glutamine, serine, threonine, tyrosine, cysteine ), nonpolar 
side chains (e.g., alanine, valine, leucine, isoleucine, pro line, 
phenylalanine, methionine, tryptophan), beta-branched side 
chains (e.g., threonine, valine, isoleucine) and aromatic side 
chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). 
Thus, a predicted nonessential amino acid residue in a 
transcriptionally regulated protein is preferably replaced 
with another amino acid residue from the same side chain 
family. Alternatively, in another embodiment, mutations can 
be introduced randomly along all or part of a transcription-
ally regulated protein coding sequence, such as by saturation 
mutagenesis, and the resultant mutants can be screened for 
a transcriptionally regulated protein activity described 
herein to identify mutants that retain transcriptionally regu-
lated protein activity. Following mutagenesis, the encoded 
polypeptide can be expressed recombinantly and the activity 
of the polypeptide can be determined. 
Additionally, optimized nucleic acids encoding transcrip-
tionally regulated proteins can be created. As used herein, 
"optimized" refers to a nucleic acid that is genetically 
engineered to increase its expression in a given organism, to 
increase its activity in a given organism, to increase its 
secretion in a given organism. For example, to provide 
optimized nucleic acids, the DNA sequence of the gene can 
be modified to 1) comprise codons preferred by highly 
expressed genes; 2) comprise an A+ T content in nucleotide 
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base composition to that substantially found in the organism 
of interest; 3) form a initiation sequence; or 4) eliminate 
sequences that cause destabilization, inappropriate polyade-
nylation, degradation, and termination of RNA, or that form 
secondary structure hairpins or RNA splice sites. 
As used herein, "frequency of preferred codon usage" 
refers to the preference exhibited by a specific host cell in 
usage of nucleotide codons to specify a given amino acid. To 
determine the frequency of usage of a particular codon in a 
10 gene, the number of occurrences of that codon in the gene 
is divided by the total number of occurrences of all codons 
specifying the same amino acid in the gene. Similarly, the 
frequency of preferred codon usage exhibited by a host cell 
can be calculated by averaging frequency of preferred codon 
15 usage in a large number of genes expressed by the host cell. 
It is preferable that this analysis be limited to genes that are 
highly expressed by the host cell. The percent deviation of 
the frequency of preferred codon usage for a synthetic gene 
from that employed by a host cell is calculated first by 
20 determining the percent deviation of the frequency of usage 
of a single codon from that of the host cell followed by 
obtaining the average deviation over all codons. As defined 
herein, this calculation includes unique codons (i.e., ATG 
and TGG). In general terms, the overall average deviation of 
25 the codon usage of an optimized gene from that of a host cell 
is calculated using the equation lA=n=l Z Xn-Yn Xn times 
100 Z where Xn=frequency of usage for codon n in the host 
cell; Yn=frequency of usage for codon n in the synthetic 
gene; n represents an individual codon that specifies an 
30 amino acid; and the total number of codons is Z. The overall 
deviation of the frequency of codon usage, A, for all amino 
acids should preferably be less than about 25%, and more 
preferably less than about 10%. 
Hence, a nucleotide encoding a transcriptionally regulated 
35 protein can be optimized such that its distribution frequency 
of codon usage deviates, preferably, no more than 25% from 
that of highly expressed genes and, more preferably, no more 
than about 10%. In addition, consideration is given to the 
percentage G+C content of the degenerate third base. Opti-
40 mized nucleic acids of this invention also preferably have 
CG and TA doublet avoidance indices closely approximating 
those of the chosen host. More preferably these indices 
deviate from that of the host by no more than about 10-15%. 
In addition to the nucleic acids and polypeptides 
45 described above, the present invention encompasses these 
nucleic acids and polypeptides attached to a moiety. These 
moieties include, but are not limited to, detection moieties, 
hybridization moieties, purification moieties, delivery moi-
eties, reaction moieties, binding moieties, and the like. A 
50 typical group of nucleic acids having moieties attached are 
probes and primers. Probes and primers typically comprise 
a substantially isolated oligonucleotide. The oligonucleotide 
typically comprises a region of nucleotide sequence that 
hybridizes under stringent conditions to at least about 12, 
55 preferably about 25, more preferably about 40, 50 or 75 
consecutive nucleotides of a sense strand of a sequence; an 
anti-sense sequence; or naturally occurring mutants thereof. 
Primers based on a nucleotide sequence can be used in PCR 
reactions to clone transcriptionally regulated proteins and 
60 nucleotides encoding transcriptionally regulated protein 
homologs. Probes based on the nucleotides encoding tran-
scriptionally regulated proteins can be used to detect tran-
scripts or genomic sequences encoding the same or substan-
tially identical polypeptides. In preferred embodiments, the 
65 probe further comprises a label group attached thereto, e.g. 
the label group can be a radioisotope, a fluorescent com-
pound, an enzyme, or an enzyme co-factor. Such probes can 
US 7,250,406 B2 
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be used as a part of a genomic marker test kit for identifying 
cells which express a transcriptionally regulated protein, 
such as by measuring a level of a nucleotide encoding a 
transcriptionally regulated protein, in a sample of cells, e.g., 
detecting mRNA levels or determining whether a genomic 
gene has been mutated or deleted. 
20 
In alternative embodiments, the isolated nucleotide 
encoding a transcriptionally regulated protein comprises a 
nucleic acid sequence that hybridizes in 5x SSC at 55° C. to 
any of the polynucleotides as defined above. In other 10 
embodiments, the isolated nucleotide encoding a transcrip-
tionally regulated protein is modified to include a promoter 
operatively linked to a foreign nucleic acid. 
The recombinant expression vectors of the invention 
comprise a nucleic acid of the invention in a form suitable 
for expression of the nucleic acid in a host cell, which means 
that the recombinant expression vectors can include one or 
more regulatory sequences, selected on the basis of the host 
cells to be used for expression, which is operatively linked 
to the nucleic acid sequence to be expressed. As used herein 
with respect to a recombinant expression vector, "opera-
tively linked" is intended to mean that the nucleotide 
sequence of interest is linked to the regulatory sequence(s) 
in a manner which allows for expression of the nucleotide 
sequence (e.g., in an in vitro transcription/translation system 
or in a host cell when the vector is introduced into the host 
cell). The term "regulatory sequence" is intended to include 
promoters, enhancers, and other expression control elements 
(e.g., polyadenylation signals). Such regulatory sequences 
In particular, a useful method to ascertain the level of 
transcription of a gene (an indicator of the amount of mRNA 15 
available for translation to the gene product) is to perform a 
Northern blot. For reference, see, for example, Ausubel et 
al., 1988, Current Protocols in Molecular Biology, Wiley: 
are described, for example, in Goedde!, Gene Expression 
Technology: Methods in Enzymology 185, Academic Press, 
San Diego, Calif. (1990) and Gruber and Crosby, in: Meth-New York The information from a Northern blot at least 
partially demonstrates the degree of transcription of the 
transformed gene. Total cellular RNA can be prepared from 
cells, tissues or organs by several methods, all well-known 
in the art, such as that described in Bormann, E. R. et al., 
1992, Mo!. Microbial. 6:317-326. To assess the presence or 
relative quantity of polypeptide translated from this mRNA, 
standard techniques, such as a Western blot, may be 
employed. These techniques are well known to one of 
ordinary skill in the art. See, for example, Ausubel et al., 
1988, Current Protocols in Molecular Biology, Wiley: New 
York 
The invention further provides an isolated recombinant 
expression vector comprising an isolated nucleic acid encod-
ing a transcriptionally regulated protein as described above, 
wherein expression of the vector in a host cell results in 
decreased stability of the mRNA encoding for the protein 
and/or decreased secretion of the protein compared to a 
wild-type variety of the host cell, or compared to a host cell 
that is expressing a vector comprising one copy of the 
isolated nucleotide encoding a transcriptionally regulated 
protein, wherein there are no supplementary nucleic acid 
sequences interposed between the stop codon of the portion 
of the mRNA transcript encoding for the transcriptionally 
regulated protein and the polyadenylation sequence. As used 
herein, the term "vector" refers to a nucleic acid molecule 
capable of transporting another nucleic acid to which it has 
been linked. One type of vector is a "plasmid," which refers 
to a circular double stranded DNA loop into which addi-
tional DNA segments can be ligated. Another type of vector 
is a viral vector, wherein additional DNA segments can be 
ligated into the viral genome. Certain vectors are capable of 
autonomous replication in a host cell into which they are 
introduced (e.g., bacterial vectors having a bacterial origin 
of replication and episomal mannnalian vectors). Other 
vectors (e.g., non-episomal mammalian vectors) are inte-
grated into the genome of a host cell upon introduction into 
the host cell, and thereby are replicated along with the host 
genome. Moreover, certain vectors are capable of directing 
the expression of genes to which they are operatively linked. 
Such vectors are referred to herein as "expression vectors." 
In general, expression vectors of utility in recombinant DNA 
techniques are often in the form of plasmids. In the present 
specification, "plasmid" and "vector" can be used inter-
changeably as the plasmid is the most commonly used form 
of vector. However, the invention is intended to include such 
other forms of expression vectors, such as viral vectors (e.g., 
replication defective retroviruses, adenoviruses, and adeno-
associated viruses), which serve equivalent functions. 
20 ads in Plant Molecular Biology and Biotechnology, Eds. 
Glick and Thompson, Chapter 7, 89-108, CRC Press: Boca 
Raton, Fla., including the references therein. For appropriate 
enhancer and other expression control sequences, see also 
Enhancers and Eukaryotic Gene Expression, Cold Spring 
25 Harbor Press, N.Y. (1983). Regulatory sequences include 
those that direct constitutive expression of a nucleotide 
sequence in many types of host cells and those that direct 
expression of the nucleotide sequence only in certain host 
cells or under certain conditions. It will be appreciated by 
30 those skilled in the art that the design of the expression 
vector can depend on such factors as the choice of the host 
cell to be transformed, the level of expression of polypeptide 
desired, etc. The expression vectors of the invention can be 
introduced into host cells to thereby produce polypeptides or 
35 peptides, including fusion polypeptides or peptides, encoded 
by nucleic acids as described herein (e.g., transcriptionally 
regulated proteins, mutant forms of transcriptionally regu-
lated proteins, fusion polypeptides, etc.). 
The recombinant expression vectors of the invention can 
40 be designed for expression of transcriptionally regulated 
proteins in prokaryotic or eukaryotic cells. For example, 
genes encoding transcriptionally regulated proteins can be 
expressed in bacterial cells such as C. glutamicum, insect 
cells (using baculovirus expression vectors), yeast and other 
45 fungal cells (See Romanos, M.A. et al., 1992, Foreign gene 
expression in Yeast: a Review, Yeast 8:423-488; van den 
Hondel, C. A. M. J. J. et al., 1991, Heterologous gene 
expression in filamentous fungi, in: More Gene Manipula-
tions in Fungi, J. W. Bennet & L. L. Lasure, Eds., p.396-428: 
50 Academic Press: San Diego; and van den Hondel, C. A. M. 
J. J. & Punt, P. J., 1991, Gene transfer systems and vector 
development for filamentous fungi, in: Applied Molecular 
Genetics of Fungi, Peberdy, J. F. et al., eds., p. 1-28, 
Cambridge University Press: Cambridge), algae (Falciatore 
55 et al., 1999, Marine Biotechnology 1(3):239-251), ciliates, 
multicellular plant cells (See Schmidt, R. and Willmitzer, L., 
1988, High efficiency Agrobacterium tumefaciens-mediated 
transformation of Arabidopsis thaliana leaf and cotyledon 
explants, Plant Cell Rep. 583-586; Plant Molecular Biology 
60 and Biotechnology, C Press, Boca Raton, Fla., chapter 6/7, 
S.71-119 (1993); F. F. White, B. Jenes et al., Techniques for 
Gene Transfer, in: Transgenic Plants, Vol.1, Engineering 
and Utilization, Eds. Kung And R. Wu, 128-43, Academic 
Press: 1993; Potrykus, 1991, Annu. Rev. Plant Physiol. Plant 
65 Malec. Biol. 42:205-225 and references cited therein) or 
mammalian cells. In a preferred embodiment, the host cell is 
a mammalian cell, and more preferably, is a human cell. In 
US 7,250,406 B2 
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one preferred embodiment, the human cell is a non-~ cell. 
Suitable host cells are discussed further in Goedde!, Gene 
Expression Technology: Methods in Enzymology 185, Aca-
demic Press: San Diego, Calif. (1990). Alternatively, the 
recombinant expression vector can be transcribed and trans- 5 
lated in vitro, for example using T7 promoter regulatory 
sequences and T7 polymerase. 
Expression of polypeptides in prokaryotes is most often 
carried out with vectors containing constitutive or inducible 
promoters directing the expression of either fusion or non- 10 
fusion polypeptides. Fusion vectors add a number of amino 
acids to a polypeptide encoded therein, usually to the amino 
terminus of the recombinant polypeptide but also to the 
C-terminus or fused within suitable regions in the polypep-
tides. Such fusion vectors typically serve three purposes: 1) 15 
to increase expression of a recombinant polypeptide; 2) to 
increase the solubility of a recombinant polypeptide; and 3) 
to aid in the purification of a recombinant polypeptide by 
acting as a ligand in affinity purification. Often, in fusion 
expression vectors, a proteolytic cleavage site is introduced 20 
at the junction of the fusion moiety and the recombinant 
polypeptide to enable separation of the recombinant 
polypeptide from the fusion moiety subsequent to purifica-
tion of the fusion polypeptide. Such enzymes, and their 
cognate recognition sequences, include Factor Xa, thrombin, 25 
and enterokinase. 
Typical fusion expression vectors include pGEX (Phar-
macia Biotech Inc; Smith, D. B. and Johnson, K. S., 1988, 
Gene 67:31-40), pMAL (New England Biolabs, Beverly, 
Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse 30 
glutathione S-transferase (GST), maltose E binding 
polypeptide, or polypeptide A, respectively, to the target 
recombinant polypeptide. In one embodiment, the coding 
sequence of the transcriptionally regulated protein is cloned 
into a pGEX expression vector to create a vector encoding 35 
a fusion polypeptide comprising, from the N-terminus to the 
C-terminus, GST-thrombin cleavage site-X polypeptide. The 
fusion polypeptide can be purified by affinity chromatogra-
phy using glutathione-agarose resin. Recombinant transcrip-
tionally regulated proteins unfused to GST can be recovered 40 
by cleavage of the fusion polypeptide with thrombin. 
Examples of suitable inducible non-fusion E. coli expres-
sion vectors include pTrc (Amann et al., 1988, Gene 69:301-
315) and pET lid (Studier et al., Gene Expression Technol-
ogy: Methods in Enzymology 185, Academic Press, San 45 
Diego, Calif. (1990) 60-89). Target gene expression from the 
pTrc vector relies on host RNA polymerase transcription 
from a hybrid trp-lac fusion promoter. Target gene expres-
sion from the pET lid vector relies on transcription from a 
T7 gnlO-lac fusion promoter mediated by a co-expressed 50 
viral RNA polymerase (T7 gnl). This viral polymerase is 
supplied by host strains BL21(DE3) or HMS! 74(DE3) from 
a resident A prophage harboring a T7 gnl gene under the 
transcriptional control of the lac UV 5 promoter. 
One strategy to maximize recombinant polypeptide 55 
expression is to express the polypeptide in a host bacteria 
with an impaired capacity to proteolytically cleave the 
recombinant polypeptide (Gottesman, S., Gene Expression 
Technology: Methods in Enzymology 185, Academic Press, 
San Diego, Calif. (1990) ll9-128). Another strategy is to 60 
alter the sequence of the nucleic acid to be inserted into an 
expression vector so that the individual codons for each 
amino acid are those preferentially utilized in the bacterium 
chosen for expression, such as C. glutamicum (Wada et al., 
1992, Nucleic Acids Res. 20:21ll-2ll8). Such alteration of 65 
nucleic acid sequences of the invention can be carried out by 
standard DNA synthesis techniques. 
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In another embodiment, the transcriptionally regulated 
protein expression vector is a yeast expression vector. 
Examples of vectors for expression in yeast S. cerevisiae 
include pYepSecl (Baldari, et al., 1987, EMBO J. 6:229-
234), pMFa (Kurjan and Herskowitz, 1982, Cell 30:933-
943), pJRY88 (Schultz et al., 1987, Gene 54:ll3-123), and 
pYES2 (Invitrogen Corporation, San Diego, Calif.). Vectors 
and methods for the construction of vectors appropriate for 
use in other fungi, such as the filamentous fungi, include 
those detailed in: van den Hondel, C. A. M. J. J. & Punt, P. 
J ., 1991, Gene transfer systems and vector development for 
filamentous fungi, in: Applied Molecular Genetics of Fungi, 
J. F. Peberdy, et al., eds., p. 1-28, Cambridge University 
Press: Cambridge. 
Alternatively, the transcriptionally regulated proteins of 
the invention can be expressed in insect cells using bacu-
lovirus expression vectors. Baculovirus vectors available for 
expression of polypeptides in cultured insect cells (e.g., Sf9 
cells) include the pAc series (Smith et al., 1983, Mal. Cell 
Biol. 3:2156-2165) and the pVL series (Lucklow and Sum-
mers, 1989, Virology 170:31-39). 
In yet another embodiment, a transcriptionally regulated 
protein nucleic acid of the invention is expressed in mam-
malian cells using a mammalian expression vector. 
Examples of mammalian expression vectors include 
pCDM8 (Seed, B., 1987, Nature 329:840) and pMT2PC 
(Kaufman et al., 1987, EMBO J. 6:187-195). When used in 
mammalian cells, the expression vector's control functions 
are often provided by viral regulatory elements. For 
example, commonly used promoters are derived from 
polyoma, Adenovirus 2, cytomegalovirus, and Simian Virus 
40. For other suitable expression systems for both prokary-
otic and eukaryotic cells, see chapters 16 and 17 of Sam-
brook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: 
A Laboratory Manual, 2nd Ed., Cold Spring Harbor Labo-
ratory, Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, N.Y., 1989. 
In another embodiment, the recombinant mammalian 
expression vector is capable of directing expression of the 
nucleic acid preferentially in a particular cell type (e.g., 
tissue-specific regulatory elements are used to express the 
nucleic acid). Tissue-specific regulatory elements are known 
in the art. Non-limiting examples of suitable tissue-specific 
promoters include the albumin promoter (liver-specific; 
Pinkert et al., 1987, Genes Dev. 1:268-277), lymphoid-
specific promoters (Calame and Eaton, 1988, Adv. Immunol. 
43:235-275), in particular promoters of T cell receptors 
(Winoto & Baltimore, 1989, EMBO J. 8:729-733) and 
immunoglobulins (Banerji et al., 1983, Cell 33:729-740; 
Queen & Baltimore, 1983, Cell 33:741-748), neuron-spe-
cific promoters (e.g., the neurofilament promoter; Byrne & 
Ruddle, 1989, PNAS 86:5473-5477), pancreas-specific pro-
moters (Edlund et al., 1985, Science 230:912-916), and 
mammary gland-specific promoters (e.g., milk whey pro-
moter; U.S. Pat. No. 4,873,316 and European Application 
Publication No. 264,166). Developmentally-regulated pro-
moters are also encompassed, for example, the murine hox 
promoters (Kessel & Gruss, 1990, Science 249:374-379) and 
the fetopolypeptide promoter (Campes & Tilghman, 1989, 
Genes Dev. 3:537-546). 
For stable transfection of mammalian cells, it is known 
that, depending upon the expression vector and transfection 
technique used, only a small fraction of cells may integrate 
the foreign DNA into their genome. In order to identify and 
select these integrants, a gene that encodes a selectable 
marker (e.g., resistance to antibiotics) is generally intro-
duced into the host cells along with the gene of interest. As 
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scope of the term as used herein. A host cell can be any 
prokaryotic or eukaryotic cell. For example, a transcription-
ally regulated protein can be expressed in bacterial cells 
such as C. glutamicum, insect cells, fungal cells, or mam-
malian cells (such as Chinese hamster ovary cells (CHO) or 
COS cells), algae, ciliates, plant cells, fungi, or other micro-
organisms like C. glutamicum. Similarly, a isolated nucle-
otide encoding a transcriptionally regulated protein can be 
introduced into any prokaryotic or eukaryotic cell, such as 
used herein, the term "selectable marker" refers to a gene 
encoding a protein necessary for the survival or growth of a 
host cell transformed with the vector. Although such a 
marker gene may be carried on another polynucleotide 
sequence co-introduced into the host cell, it is most often 
contained on the cloning vector. Only those host cells into 
which the marker gene has been introduced will survive 
and/or grow under selective conditions. Typical selection 
genes encode proteins that (a) confer resistance to antibiotics 
or other toxic substances, e.g., ampicillin, neomycin, meth-
otrexate, etc.; (b) complement auxotrophic deficiencies; or 
( c) supply critical nutrients not available from complex 
media. The choice of the proper selectable marker will 
depent on the host cell; appropriate markers for different 
hosts are known in the art. 
10 bacterial cells, insect cells, fungal cells, or mammalian cells, 
algae, ciliates, plant cells, fungi, or other microorganisms. In 
preferred embodiments, the host cell is a mammalian cell. In 
other preferred embodiments, the host cell is a non-~ cell. In 
other preferred embodiments, the host cell is a hepatic cell. 
Other suitable methods for transforming or transfecting 
host cells can be found in Sambrook, et al., Molecular 
Cloning: A Laboratory Manual. 2nd Ed., Cold Spring Har-
bor Laboratory, Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor, N.Y., 1989, and other laboratory manuals. 
15 In a particularly preferred embodiment, the host cell is a 
human hepatic cell. In other preferred embodiments, the host 
cell is an autologous cell. In other preferred embodiments, 
the host cell is an immortalized cell line. Preferred immor-
talized cell line include hepatic cell lines, and in particular, 
20 the human HepG2 cell line. Other suitable host cells and cell 
lines are known to those skilled in the art. Because routine In another embodiment, recombinant organisms can be 
produced that contain selected systems which allow for 
regulated expression of the introduced gene. For example, 
inclusion of a gene encoding a transcriptionally regulated 
protein on a vector placing it under control of the lac operon 25 
permits expression of the gene encoding a transcriptionally 
regulated protein only in the presence of IPTG. Such regu-
latory systems are well known in the art. 
Gene expression should be operatively linked to an appro-
priate promoter conferring gene expression in a timely, cell 30 
or tissue specific manner. Promoters useful in the expression 
cassettes of the invention include any promoter that is 
capable of initiating transcription in a cell. 
The promoter may be constitutive, inducible, develop-
mental stage-preferred, cell type-preferred, tissue-preferred, 35 
or organ-preferred. Constitutive promoters are active under 
most conditons. Examples of constitutive promoters include 
the CaMV 19S and 35S promoters (Odell et al., 1985, 
Nature 313:810-812), the sX CaMV 35S promoter (Kay et 
al., 1987, Science 236:1299-1302) the Sepl promoter, the 40 
ubiquitin promoter (Christensen et al., 1989, Plant Malec 
Biol 18:675-689); pEmu (Last et al., 1991, Theor. Appl. 
Genet. 81:581-588), and the like. 
Inducible promoters are active under certain environmen-
tal conditions, such as the presence or absence of a nutrient 45 
or metabolite, heat or cold, light, pathogen attack, anaerobic 
conditons, and the like. Chemically inducible promoters are 
especially suitable if gene expression is wanted to occur in 
errors of gene expression due to premature termination of 
translation are inevitable and truncated proteins generated 
by nonsense mutant mRNAs are potentially toxic to cells, it 
is expected that all the mannnalian cells have evolved to 
recognize mRNAs containing premature termination codons 
and host nonsense mediated mRNA decay. Specifically, 
NMD has been demonstrated in lymphoblasts (Rajavel, K. 
S. & Neufeld, E. F. 2001, Mo!. Cell Biol. 21:5512-9), 
fibroblasts (Zhang, J., et al. 1998, Mo!. Cell Biol. 18:5272-
83), chondrocytes (Bateman, J. F., et al. 2003, Hum. Mo!. 
Genet. 12:217-25), and Chinese hamster ovary (CHO) cells 
(Kessler, 0. & Chasin, L.A. 1996, Mo!. Cell Biol. 16:4426-
35), among others. Thus, any host cell or cell line that 
recognize premature termination codons and responds by 
inducing nonsense mediated mRNA decay are candidates for 
the application of the invention described herein. 
A host cell of the invention, such as a eukaryotic host cell 
in culture, can be used to produce (i.e., express) a transcrip-
tionally regulated protein. Accordingly, the invention further 
provides methods for producing transcriptionally regulated 
proteins using the host cells of the invention. In one embodi-
ment, the method comprises culturing the host cell of 
invention (into which a recombinant expression vector 
encoding a transcriptionally regulated protein has been 
introduced, or into which genome has been introduced a 
gene encoding a wild-type or altered transcriptionally regu-
lated protein) in a suitable medium until transcriptionally 
regulated protein is produced. In another embodiment, the 
method encompasses the introduction of a heterologous 
isolated nucleotide encoding a transcriptionally regulated 
protein, resulting in a down-regulation in secretion of the 
transcriptionally regulated protein. 
A host cell of the invention, such as a eukaryotic host cell 
a time specific manner. Developmental stage-preferred pro-
moters are preferentially expressed at certain stages of 50 
development. Additional flexibility in controlling heterolo-
gous gene expression may be obtained by using DNA 
binding domains and response elements from heterologous 
sources (i.e., DNA binding domains from non-mannnalian 
sources). 55 in culture, can be used to treat a patient in need thereof, 
comprising administering to the patient a therapeutically 
effective amount of the cell. In a preferred embodiment, the 
cell comprises a heterologous nucleic acid comprising a 
preproinsulin encoding nucleic acid. In a preferred embodi-
Another aspect of the invention pertains to host cells into 
which a heterologous nucleic acid of the invention has been 
introduced. The terms "host cell" and "recombinant host 
cell" are used interchangeably herein. It is understood that 
such terms refer not only to the particular subject cell but 
they also apply to the progeny or potential progeny of such 
a cell. As such, both the original host cell that contains the 
heterologous nucleic acid of the invention and any progeny 
cells are transgenic. Because certain modifications may 
occur in succeeding generations due to either mutation or 
environmental influences, such progeny may not, in fact, be 
identical to the parent cell, but are still included within the 
60 ment, the nucleic acid encodes human insulin. In a preferred 
embodiment, the patient treated with the host cell of the 
invention has diabetes. In a further preferred embodiment, 
the disease is insulin-dependent diabetes. 
Standard techniques for cloning, DNA isolation, amplifi-
65 cation and purification, for enzymatic reactions involving 
DNA ligase, DNA polymerase, restriction endonucleases 
and the like, various separation techniques, and techniques 
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to analyze mRNA and proteins are those known and com-
monly employed by those skilled in the art. A number of 
standard techniques are described in Sambrook et al:, 1989 
Molecular Cloning, Second Edition, Cold Spring Harbor 
Laboratory, Plainview, N.Y.; Maniatis et al., 1982 Molecular 5 
Cloning, Cold Spring Harbor Laboratory, Plainview, N.Y; 
Wu (Ed.) 1993 Meth. Enzymol. 218, Part I; Wu (ed.) 1979 
Meth. Enzymol. 68; Wu et al., (Eds.) 1983 Meth. Enzymol. 
100 and 101; Grossman and Moldave (Eds.) 1980 Meth. 
Enzymol. 65; Miller (Ed.) 1972 Experiments in Molecular 10 
Genetics, Cold Spring Harbor Laboratory, Cold Spring 
Harbor, N.Y.; Old and Primrose, 1981 Principles of Gene 
Manipulation, University of California Press, Berkeley; 
Schleif and Wensink, 1982 Practical Methods in Molecular 
Biology; Glover (Ed.) 1985 DNA Cloning Vol. I and II, IRL 15 
Press, Oxford, UK; Hames & Higgins (Eds.) 1985 Nucleic 
Acid Hybridization, IRL Press, Oxford, UK; and Setlow & 
Hollaender 1979 Genetic Engineering: Principles and Meth-
ods, Vols. 1-4, Plenum Press, New York. Abbreviations and 
nomenclature, where employed, are deemed standard in the 20 
field and commonly used in professional journals such as 
those cited herein. 
pRL/Null (Promega, Madison, Wis.), having the sequence 
5'-CAGGTAAGTATCAAGGTTACAAGACAG-
GTTTAAGGAGACCAATAGAAACTGGGCTT 
GAGACAGAGAAGACTCTTGCGTTTCT-
GTC-
GATAGGCACCTATTGGTCTTACTGACAT 
CCACTTTGCCTTTCTCTCCACAGG-3' (SEQ ID NO:I). 
The chimeric intron is included in the insulin expression 
cassette for optimal splicing since studies have demonstrated 
that splicing is important for mRNA transport across the 
nucleus membrane (Luo, M.-J. & Reed, R., 1999 Proc. Natl. 
Acad. Sci. USA, 96: 14937-42) and the incorporation of an 
intron in an expression cassette can improve the levels of 
recombinant gene expression (Huang, M. T. & Gorman, C. 
M., 1990 Nucleic Acids Res. 18:937-47). 
The backbone of the Tet-responsive insulin expression 
plasmid was obtained from a 2074 bp XhoI/XbaI fragment 
of plasmid pRL/Null (Promega). The tetracycline-respon-
sive promoter was obtained from a 448 bp XhoI/EcoRI 
restriction fragment of plasmid pTRE2pur (Clontech, Palo 
Alto, Calif.). This promoter was inserted into the multiple 
cloning sites of pRL/Null. For the control plasmid contain-
ing one copy of insulin gene, a 360 bp XbaI/XbaI restriction 
fragment containing the furin-compatible insulin gene with 
BIO mutation was connected to the backbone using NheI 
Tbroughout this application, various publications are ref-
erenced. The disclosures of all of these publications and 
those references cited within those publications in their 
entireties are hereby incorporated by reference into this 
application in order to more fully describe the state of the art 
25 and XbaI sites (vector F). For the engineered plasmid, two 
additional copies of the insulin gene were consecutively 
inserted to the backbone via the XbaI site with the same 
head-tail configuration (vector G). After transcription, the to which this invention pertains. The following examples are 
not intended to limit the scope of the claims to the invention, 
but are rather intended to be exemplary of certain embodi- 30 
ments. Any variations in the exemplified methods which 
occur to the skilled artisan are intended to fall within the 
engineered PPI mRNA contained three consecutive copies 
of the insulin gene with stop codons in the middle of the 
transcript. Translation is expected to stop in the middle of 
the engineered PPI mRNA and induce NMD. The Xhol/ 
XhoI restriction fragments of the Clontech plasmids cat# 
Kl620-A and Kl621-A were used to prepare plasmids 
scope of the present invention. 
EXAMPLES 
Example I 
PPI mRNA Engineering and Expression 
Plasmids for Insulin Expression 
Vectors A-E in FIG. 1 are five plasmids constructed to 
systematically increase insulin expression in HepG2 cells. 
Wild-type human preproinsulin cDNA, furin-compatible 
with furin cleavage sites at the B-C and C-Ajunctions, and 
furin-compatible with His BIO-to-Asp mutation (BIO muta-
tion) were all generous gifts from Genentech, Inc (San 
Francisco, Calif.; see Groskreutz, et al., C. M., 1994, J. Biol. 
Chem. 269:6241-5). The backbone of the insulin expression 
plasmids originated from an 1822 bp BglII/BamHI fragment 
of plasmid pRL/Null (Promega, Madison, Wis.). A 508 bp 
XbaI/BamHI restriction fragment containing both the Sim-
ian Virus 40 (SV40) late polyadenylation and SV40 
enhancer signals from plasmid pGL3-control (Promega) was 
used to replace the SV40 late polyadenylation signal in 
pRL/Null to prepare the plasmid with the SV 40 enhancer. 
The human cytomegalovirus (CMV) promoter used to drive 
the insulin gene expression was obtained from an 883 bp 
BglII/NheI restriction fragment of plasmid pcDNA3. I ( +) 
(Invitrogen, Carlsbad, Calif.). The CMV promoter was con-
nected to the Bg!II and SpeI sites of pRL/Null to prepare the 
plasmid with an intron, or to the Bg!II and NheI sites to 
prepare the plasmid without an intron. Different versions of 
XbaI/XbaI preproinsulin cDNA fragment were connected to 
the backbones using NheI and XbaI sites. 
The intron connected to the 5' of preproinsulin gene was 
the 13 7-bp chimeric intron from the backbone plasmid 
35 pTet-Off and pTet-On, respectively. 
The sequence of the His BIO-to-Asp mutated human PPI 
cDNA with furin cleavage sites at the B-C and C-Ajunctions 
1s 5'- ATGGCCCTGTGGATGCGCCTCCTGC-
CCCTGCTG GCGCTGCTGGCCCTCTGGGGACCT-
40 GACCCAGCCGCAGCCTTTGTGAACCAACACCTG 
TGCGGATCCGACCTGGTGGAAGCTCTC-
TACCTAGTGTGCGGGGAACGAGGCTTCTTC TACA-
CACCCAGGACCAAGCGGGAGGCAGAG-
GACCTGCAGGTGGGGCAGGTGGAGC 
45 TGGGCGGGGGCCCTGGTGCAGGCAGCCT-
GCAGCCCTTGGCCCTGGAGGGATCCCGG 
CAGAAGCGTGGCATTGTGGAACAATGCT-
GTACCAGCATCTGCTCCCTCTACCAGCTG 
GAGAACTACTGCAACTAG-3' (SEQ ID N0:2). The 
50 sequence of the three copies of the His BIO-to-Asp mutated 
human PPI cDNA with furin cleavage sites at the B-C and 
C-A junctions is 5'-CTAGAGTCGACCTGCAGAAGCT-
TACCATGGCCCTGTGGATGCGCCTCCTGCCCCTG 
CTGGCGCTGCTGGCCCTCTGGGGACCT-
55 GACCCAGCCGCAGCCTTTGTGAACCAACA CCTGT-
GCGGATCCGACCTGGTGGAAGCTCTC-
TACCTAGTGTGCGGGGAACGAGGC 
TTCTTCTACACACCCAGGACCAAGCGG-
GAGGCAGAGGACCTGCAGGTGGGGCAGG 
60 TGGAGCTGGGCGGGGGCCCTGGTGCAG-
GCAGCCTGCAGCCCTTGGCCCTGGAGGG ATCCCG-
GCAGAAGCGTGGCATTGTGGAACAA~ 
GCTGTACCAGCATCTGCTCCCTCT 
ACCAGCTGGAGAACTACTGCAAC-
65 TAGTCTAGAGTCGACCTGCAGAAGCTTACCAT 
GGCCCTGTGGATGCGCCTCCTGCCCCT-
GCTGGCGCTGCTGGCCCTCTGGGGACCTG 
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CAATGCTGTACCAGCATCTGCTCCCTC-
TACCAGCTGGAGAACTACTGCAACT AGTCTAGA-3' 
(SEQ ID N0:4) 
The amino acid sequence corresponding to the mutated 
ACCCAGCCGCAGCCTTTGTGAACCAA-
CACCTGTGCGGATCCGACCTGGTGGAAGC TCTC-
TACCTAGTGTGCGGGGAACGAGGCTTCT-
TCTACACACCCAGGACCAAGCGG 
GAGGCAGAGGACCTGCAGGTGGGGCAG-
GTGGAGCTGGGCGGGGGCCCTGGTGCA GGCAGC-
CTGCAGCCCTTGGCCCTGGAGGGATC-
CCGGCAGAAGCGTGGCATTGTGG 
AACAATGCTGTACCAGCATCTGCTC-
CCTCTACCAGCTGGAGAACTACTGCAACTAG 
AGTCGACCTGCAGAAGCTTACCATGGC-
5 human preproinsulin as defined in SEQ ID N0:2 is Met-
ala-leu-trp-met-arg-leu-leu-pro-leu-leu-ala-leu-leu-ala-leu-
trp-gly-pro-asp-pro-ala-ala-ala-phe-val-asn-gln-his-leu-cys-
gly-ser-
.a.sp_-leu-val-glu-ala-leu-tyr-leu-val-cys-gly-glu-arg-gly-phe-
CCTGTGGATGCGCCTCCTGCCCCTGCTGG CGCT-
GCTGGCCCTCTGGGGACCTGACCCAGC-
CGCAGCCTTTGTGAACCAACACCTG 
TGCGGATCCGACCTGGTGGAAGCTCTC-
TACCTAGTGTGCGGGGAACGAGGCTTCTT CTACA-
CACCCAGGACCAAGCGGGAGGCAGAG-
GACCTGCAGGTGGGGCAGGTGGA 
GCTGGGCGGGGGCCCTGGTGCAGGCAGC-
1 o phe-tyr-thr-pro-arg-thr-lvs-arg-glu-ala-glu-asp-leu-gln-val-
gly-gln-val-glu-leu-gly-gly-gly-pro-gly-ala-gly-ser-leu-gln-
pro-leu-ala-leu-glu-gly-ser-arg-gln-lys-arg-gly-ile-val-glu-
gln-cys-cys-thr-ser-ile-cys-ser-leu-tyr-gln-leu-glu-asn-tyr-
cys-asn-* (SEQ ID N0:5). The asterisk (*) indicates the 
15 presence of a termination codon. The underlined amino acid 
residues indicate the positions of mutation in comparison to 
wild-type human preproinsulin. The nucleic acid sequences 
and amino acid sequences for preproinsulin and insulin of 
CTGCAGCCCTTGGCCCTGGAGGGATCC CGGCA- 20 
GAAGCGTGGCATTGTGGAACAATGCTG-
TACCAGCATCTGCTCCCTCTACC 
AGCTGGAGAACTACTGCAACTAGTCTAGA-3' (SEQ 
ID N0:3). 
other animal species, and variants within a species such as 
human, are well-known and publicly available. 
Cell Culture and Transfection 
HepG2 human hepatoma cells (ATCC, Manassas, Va.) 
were grown in DMEM supplemented with 10% fetal bovine 
serum, 1.1 mg/ml sodium pyruvate and 100 units/ml peni-
cillin/streptomycin at 37° C. in a 5% C02/95% air humidi-
fied atmosphere. Approximately 106 cells were seeded in 
each 9.6 cm2 well of 6-well plates and were fed with 2 ml 
culture medium for 8-12 hours prior to transfection. All 
30 transfections were carried out with FUGENE 6 reagent (Roche, Indianapolis, Ind.) following the manufacturer's 
directions. For each well, HepG2 cells were transfected for 
24 hours with the plasmid DNA cocktail (2.1 µg or 2.25 µg) 
and 6 PI ofFUGENE 6 reagent. Unless otherwise specified, 
The sequence of the intron plus three copies of the 25 
mutated human insulin as described above is 5'CAGG-
TAAGTATCAAGGTTACAAGACAGGTT-
TAAGGAGACCAAT AGAAACTGGGCTTGTCGAGA-
CAGAGAAGACTCTTGCGTTTCTGATAGGCACCTAT 
TGGTCTTACTGACATCCACTTTGC-
CTTTCTCTCCACAGGCTAGAGTCGACCTGCAG 
AAGCTTACCATGGCCCTGTGGATGCGC-
CTCCTGCCCCTGCTGGCGCTGCTGGCCCT CTGGG-
GACCTGACCCAGCCGCAGCCTTTGT-
GAACCAACACCTGTGCGGATCCGACC 
TGGTGGAAGCTCTCTACCTAGTGT-
GCGGGGAACGAGGCTTCTTCTACACACCCAGG 
ACCAAGCGGGAGGCAGAGGACCTGCAG-
GTGGGGCAGGTGGAGCTGGGCGGGGGC CCTGG~ 
GCAGGCAGCCTGCAGCCCTTGGCCCTG-
GAGGGATCCCGGCAGAAGCGTG 
GCATTGTGGAACAATGCTGTACCAG-
CATCTGCTCCCTCTACCAGCTGGAGAACTAC 
TGCAACTAGTCTAGAGTCGACCTGCA-
GAAGCTTACCATGGCCCTGTGGATGCGCCT CCTGC- 45 
CCCTGCTGGCGCTGCTGGCCCTCTGGG-
GACCTGACCCAGCCGCAGCCTTTG 
TGAACCAACACCTGTGCGGATCCGAC-
CTGGTGGAAGCTCTCTACCTAGTGTGCGGG GAAC-
GAGGCTTCTTCTACACACCCAGGAC-
CAAGCGGGAGGCAGAGGACCTGCAGG 
TGGGGCAGGTGGAGCTGGGCGGGGGC-
CCTGGTGCAGGCAGCCTGCAGCCCTTGGC CCTG-
GAGGGATCCCGGCAGAAGCGTGGCAT-
TGTGGAACAATGCTGTACCAGCATC 
TGCTCCCTCTACCAGCTGGAGAACTACT-
GCAACTAGAGTCGACCTGCAGAAGCTTA CCATG-
GCCCTGTGGATGCGCCTCCTGCCCCT-
GCTGGCGCTGCTGGCCCTCTGGGGA 
CCTGACCCAGCCGCAGCCTTTGTGAAC-
CAACACCTGTGCGGATCCGACCTGGTGGA 
AGCTCTCTACCTAGTGTGCGGGGAAC-
GAGGCTTCTTCTACACACCCAGGACCAAGC 
GGGAGGCAGAGGACCTGCAG-
GTGGGGCAGGTGGAGCTGGGCGGGGGCCCTGGTG 65 
CAGGCAGCCTGCAGCCCTTGGCCCTG-
GAGGGATCCCGGCAGAAGCGTGGCATTGT GGAA-
35 transfected cells were incubated in culture medium for 
another 24-36 hours for recovery. Cells were then washed 
and incubated with culture medium for two consecutive 
I-hour periods to stabilize insulin secretion before any tests 
were performed. 
40 Systematic Increase of Insulin Expression 
HepG2 cells were transiently transfected using 2 µg oftest 
plasmid (FIG. 1, vector A, B, C, D or E) and 0.1 µg of 
plasmid pGL3-Control (Promega) for luciferase expression 
as internal standard. Cells were then incubated for 1 hour in 
culture medium, which was collected to assay for secreted 
insulin. Cells were detached using 2.5 ml 0.25% trypsin 
solution supplemented with 5 mg of collagenase type II for 
luciferase assay and cell counting. 
50 Assay 
Firefly luciferase activity from the internal control vector 
pGL3-Control was measured using the luciferase assay 
system (Promega) following the manufacturer's protocol 
and using an LS 5000 scintillation counter (Beckman, Ful-
55 lerton, Calif.). Secreted insulin was measured by human 
insulin specific radioimmunoassay (RIA) kit (LINCO 
Research, St. Charles, Mich.). The primary antibody in the 
kit cross-reacts with proinsulin at less than 0.2%. Radioac-
tivities were determined in Auto-Ganmia Counting System, 
60 Cobra II (Packard, Meriden, Conn.). 
The change of intracellular PPI mRNA level was quan-
tified by the TaqMan real-time PCR technique (Applied 
Biosystems, Foster City, Calif.). Total RNA was isolated 
using RNeasy Mini Kit (Qiagen, Valencia, Calif.); cDNA 
was then synthesized using the Avian myoblastosis virus 
(AMY) Reverse Transcriptase Kit (Promega) to prepare 
templates for TaqMan real-time PCR. 
US 7,250,406 B2 
29 
The expression levels of PPI mRNA and of the internal 
reference tTA (tetracycline-reponsive transcriptional activa-
tor from co-transfected plasmid pTet-Off) mRNA were 
measured using probes labeled with 6FAMTM and VIC™ 
(Applied Biosystems), respectively, in separate tubes. The 
primers and probes (Table 1) were designed using Primer 
Express software (Applied Biosystems). Measuring prepro-
insulin mRNA-FAM and tTAmRNA-VIC permitted correc-
tion of discrepancies from differences in sample preparation 
and transfection efficiencies. PCR reactions were performed 10 
with the TaqMan Universal PCR Master Mix and the ABI 
PRISM 7700 Sequence Detection System (Applied Biosys-
tems) using the following thermal cycle routine: 50° C. for 
2 minutes 95° C. for 10 minutes, and then 40 cycles of 95° 
C. for 15 seconds, followed by 60° C. for 1 minute. A 15 
comparative threshold cycle (CT) method (User Bulletin 
Number 2; Applied Biosystems) was used to determine 
relative gene expression. Relative quantification of PPI 
mRNA was done by normalizing the PPI mRNA with the 
tTA mRNA signal and by assigning a value of 100 to the 20 
normalized sample level at time zero. 
TABLE 1 
30 
and a 20.7±3.8-fold higher insulin secretion rate in the 
absence relative to the presence of DOX. With the engi-
neered plasmid, the corresponding values were 20.7±3.9-
fold higher mRNA and 19.2±4.8-fold higher insulin secre-
tion rate in the absence vs. presence of DOX. 
NMD improved the secretory response ofHepG2 cells but 
also reduced intracellular PPI mRNA levels and thus 
decreased insulin expression. To ameliorate this problem, 
insulin expression was increased before applying NMD. 
HepG2 hepatomas transiently transfected with vector D 
(FIG. 1) secreted insulin at a rate of720fmole/(hr·106 cells), 
which is higher than the basal insulin secretion rate of 380 
fmole/(hr· 106 cells) exhibited by ~TC-3 mouse insulinomas 
(Mukundan, et al., 1995, Biochem. Biophys. Res. Commun. 
210: 113-8). For Tet-responsive insulin expression, although 
the SV 40 enhancer was not applied, the insulin secretion 
from Tet-Offtransfected HepG2 cells in DOX-free medium 
was 320 fmole/(hr-106 cells) and 109 fmole/(hr· 106 cells) 
when the control and engineered PPI mRNA, respectively, 
were used. 
Probe and primer sequences for TagMan real-time PCR technique. 
Gene Probe and primer sequence (5' ___,. 3') 
Insulin FAM probe: TCCGACCTGGTGGAAGCTCTCTACCTAGTG (SEQ ID N0:6) 
Forward: TTTGTGAACCAACACCTGTGC (SEQ ID N0:7) 
Reverse: GGGTGTGTAGAAGAAGCCTCGTT (SEQ ID NO:S) 
tTA VIC probe: CCCGTAAACTCGCCCAGAAGCTAGGTGT (SEQ ID N0:9) 
Forward: GGTCGGAATCGAAGGTTTAACA (SEQ ID NO:lO) 
Reverse: TGCCAATACAATGTAGGCTGCT (SEQ ID NO:ll) 
Results 
FIG. 1 shows the plasmids constructed to improve insulin 40 
expression. With the CMV promoter, vector D resulted in 
insulin secretion rates of 720± 130 fmole/(hr· 106 cells) from 
transiently transfected HepG2 hepatomas (FIG. 2). This was 
32.0±9.4 fold higher than the secretion rate achieved with 
the furin-compatible insulin gene without any gene attach- 45 
ments (FIGS. 1 and 2, vector A), and 27.5±8.0 fold higher 
relative to the wild-type insulin gene with the chimeric 
intron and SV40 enhancer (FIGS. 1 and 2, vector E). 
However, because the SV 40 enhancer is not compatible with 
the Tet-responsive system, vectors applied for Tet-respon- 50 
sive insulin expression did not contain this sequence, but 
they did contain the B-C and C-Ajunction and BIO His-to-
Asp mutations, as well as the chimeric intron. 
Example 2 
Dynamics of Insulin Expression and Secretion 
Dynamic Insulin Expression 
HepG2 cells were transiently co-transfected using 2 µg of 
plasmid pTet-Off (or pTet-On) and 0.25 µg of the control or 
engineered PPI mRNA expression plasmid (FIG. 1, vectors 
F, and G). Tet-Offtransfected cells in parallel cultures were 
incubated in doxycycline (DOX)-free medium or in medium 
with 1 µg/ml DOX for 24-36 hours. Media were renewed, 
and cells were incubated for an additional 1 hour during 
which insulin secretion was measured; cells were then lysed 
for quantitative mRNA assay. To study the dynamics of 
insulin gene down-regulation, Tet-Offtransfected cells were 
switched from DOX-free medium to 1 µg/ml DOX medium 
for 8 hours. Every hour, culture medium was renewed and 
collected for insulin assay. Every two hours, cells were lysed 
for quantitative mRNA assay. To dynamically regulate insu-
lin secretion using Tet-On system, Tet-On transfected cells 
were switched from DOX-free medium to 1 µg/ml DOX 
medium for 1 hour, washed four-times, incubated with 
DOX-free medium for 7 hours, and the steps were repeated. 
Every hour, culture medium was renewed and collected for 
insulin assay. 
The control and engineered PPI mRNA expression plas-
mids (vectors F and G, FIG. 1) were each transiently 55 
co-transfected with plasmid pTet-Off in HepG2 cells. Use of 
the engineered PPI mRNA decreased the insulin expression 
level to 109±43 fmole/(hr· 106 cells) from 320±55 fmole/ 
(hr·l06 cells) (n=4) of the control construct, or by 66%. 
Evidently, the decreased stability of engineered mRNA 60 
reduced intracellular mRNA levels and thus expression, as 
observed in many other nonsense mutations (Li, S. & 
Wilkinson, M. F., 1998, Immunity 8:135-41; Pulak, R. & 
Anderson, P., 1993, Genes. Dev. 7:1885-97). However, cells 
with both engineered and control plasmids were regulated in 65 Results 
a similar fashion by DOX. With the control plasmid, trans-
fected cells had a 24.8±5.2-fold higher mRNA expression 
The down-regulation of insulin gene expression was 
tested using the Tet-Off expression system. In the dynamic 
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test, transcription was down-regulated by exposing cells at 
time zero to culture medium with 1 µg/ml DOX (FIG. 3). 
The engineered PPI mRNA exhibited a faster decline with a 
half-life of less than 4 hours relative to the control that had 
a half-life of more than 8 hours. The decline of insulin 
secretion rate followed the similar trends. Thus, immunore-
active insulin can be synthesized from the engineered PPI 
mRNA, and that the dynamics of down-regulation upon 
switching off transcription at both the mRNA and secreted 10 
protein levels are faster with the engineered PPI mRNA 
relative to control. 
32 
Example 3 
Translation Inhibition Indicates Role of NMD in 
Insulin Secretion Dynamics 
Translation Inhibition Test 
Tet-Off transfected HepG2 cells were washed once, then 
exposed to DOX-free medium with 28 µg/ml cycloheximide 
for 4 hours (Rajavel, K. S. & Neufeld, E. F., 2001, Mo!. Cell 
Biol. 21:5512-9). The time of addition of cycloheximide-
containing medium was time 0. To resume translation, cells 
were washed four times, then incubated with DOX-free, 
cycloheximide-free medium for two consecutive 4-hour 
Up- and down-regulation of insulin secretion from trans-
fected HepG2 cells was tested using the Tet-On system, in 
which DOX induces insulin gene expression. Using 1 hour 15 periods. At 0, 4, 8, and 12 hours, cells were lysed for a 
quantitative mRNA assay. of induction in an 8-hour cycle, insulin production from the 
engineered PPI mRNA responded to the transcriptional 
switches (FIG. 4). On the other hand, insulin production 
from the control PPI mRNA failed to decline during the 20 
7-hour basal periods of exposure to DOX-free medium. 
The specificity of the Tet-Off system and the sub-toxic 
DOX concentration used in this study (Gossen, et al., 1995, 
Science 268: 1766-9) increase the fidelity of mRNA half-life 
25 
Results 
A control experiment was performed to elucidate whether 
NMD was indeed involved in shortening the half-life of the 
engineered PPI mRNA. Since normal mRNA and nonsense 
mutants are distinguished from each other via translation, 
the effect of inhibiting translation on the levels of control 
and engineered PPI mRNA was examined. HepG2 hepato-
mas transiently transfected with control or engineered PPI 
mRNA under Tet-Off control were maintained in DOX-free 
medium and exposed to cycloheximide at time 0 (FIG. 5). 
The engineered/control PPI mRNA ratio at time 0 was 
measurements compared to experiments with non-specific 
inhibitors (Ross, J., 1995, Microbial. Rev. 59,423-50). One 
concern in determining insulin secretion dynamics with the 
Tet-responsive system is the pharmacokinetics of DOX. It 
has been shown that the Tet-Off system and its transcription 
repressor tetracycline can be applied to measure the stability 
30 defined as 100%. After 4 hours of cycloheximide treatment, 
this ratio increased to 490% compared to the cycloheximide-
free culture. Upon withdrawing cycloheximide to resume 
translation, the engineered/control PPI mRNA ratio 
decreased toward the basal level. 
of a spliced intron with a half-life as low as 6 minutes 
(Clement, et al., 1999, RNA 5:206-20). Hence, it appears 
that tetracycline quickly diffuses into cells and blocks tran-
scription. It is expected that DOX, a tetracycline isomer and 35 
analogue, would have similar kinetics in regulating insulin 
gene expression in HepG2 cells However, the reverse pro-
cess of decline of intracellular DOX concentration may be 
more complicated since, besides diffusion out, processes 40 
such as dissociation of DOX from the DOX-protein com-
plex, distribution and accumulation of DOX in organelles, 
and metabolism of DOX may be occurring and contributing 
to the delays in insulin secretion down-regulation exhibited 
Example 4 
Effect of the Length of the Intervening DNA 
Sequences on mRNA Stability 
Plasmids 
The Tet-responsive plasmid with I-copy of preproinsulin 
gene is the same as Vector F (FIG. 1) in Example 1. 
Constructions of the Tet-responsive plasmids with 2, 3 and 
4 copies of preproinsulin gene were done by consecutively 
inserting 1, 2, or 3 copies of preproinsulin gene to the 3' end 
of preproinsulin gene in Vector F via the XbaI site, which is 
by the Tet-On system (FIG. 4). It is possible that with a 45 
metabolizable secretagogue, e.g., glucose, the intrinsic 
kinetics of transcription would be closer to the kinetics of 
secretion, especially during the down-regulation process. 
50 
located next to the stop codon of preproinsulin gene. In FIG. 4, two DOX square waves were applied to induce 
the Tet-On system, and obtained a 5-fold increase of insulin 
secretion from the single copy plasmid. An 8-hour induction 
was performed with the same Tet-On system, and obtained 
an approximately 30-fold increase of insulin secretion. This 
result is similar to the findings of Gossen et al. (1995, 55 
Science 268: 1766-9) using luciferase as the reporter to test 
the kinetics of the Tet-On system. Due to the stability of the 
1 copy PPI mRNA plasmid, there was no decline in insulin 
secretion rate during the two 7 hour DOX-free basal periods. 60 
However, the increase in insulin secretion from the second 
induction was significantly lower than the first. If the experi-
ment continued in the same fashion, it is expected that the 
insulin secretion would not exhibit any net increase after 
some maximum, as any (small) additional increase in secre- 65 
ti on rate upon induction would be compensated by a decline 
during the subsequent basal period. 
Assays 
Transcription levels, secretion of insulin, and the dynam-
ics of insulin gene expression and insulin secretion were 
evaluated as described in Examples 1-3. 
Results 
The down-regulation in the secretion of insulin is related 
to the copy number of the insulin gene in the construct. As 
shown in FIG. 6, when DOX was removed from the Tet-On 
system, the constructs containing 2 and 3 copies of the 
preproinsulin gene demonstrated down-regulation of insulin 
secretion, while insulin secretion of the construct containing 
1 copy of the preproinsulin gene remained relatively stable. 
Therefore, constructs containing more than one copy of the 
preproinsulin gene demonstrated a faster decline of insulin 
secretion following the down-regulation of transcription. 
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As shown in FIG. 7A, the Tet-Off system was used to 
evaluate the down-regulation of insulin secretion with con-
structs containing different copies (I to 4) of the preproin-
sulin gene. Transcription was down-regulated by adding 
DOX at time 0. Compared with the one-copy control con-
struct, systems with multiple copies of insulin gene all show 
faster decline of insulin secretion. FIG. 7B demonstrates the 
dynamics of insulin secretion with the Tet-On system when 
34 
Example 5 
The Role of the Varying the Sequence of the 
Intervening DNA Sequences 
Plasmids 
cells were exposed to a square wave of DOX induction, 10 
The luciferase gene used to generate preproinsulin-lu-
ciferase hybrid mRNA originated from plasmid pGL3-con-
trol (Promega ). To generate a SpeI site at the 5' end of the 
luciferase gene, a 226-bp BglII/HindIII adaptor obtained 
from plasmid pSE280 (Invitrogen) was used to replace the 
SV40 promoter fragment in pGL3-control; following by 
SpeI and XbaI digestions, a luciferase DNA fragment was 
which mimics the effect of glucose in stimulating the tran-
scription of insulin gene after a meal. This test indicates that 
the responses from the 3- and 4-copy systems are very 
similar. While the responses from the 3- and 4-copy systems 
are slightly faster than the response of the 2-copy system, the 
2-copy system is noticeably faster than the I-copy system. 
In addition, while the 4-copy system demonstrated an 
increased down-regulation in the secretion of insulin, due to 
the size of the constructs, the 3-copy system was easier to 
manipulate in the laboratory. However, it has been shown in 
FIGS. 7 A and 7B that all multiple-copy systems tested were 
very effective in accelerating the down-regulation of insulin 
secretion compared with the one-copy control. 
The dynamics of insulin secretion were examined using 
the I-copy, 2-copy, 3-copy, and 4-copy constructs. The 
regulation of insulin secretion from transfected HepG2 
hepatomas was evaluated using the Tet-On system as 
described in Example 2. However, rather than using a I hour 
DOX induction as described in Example 2, a 2 hour DOX 
induction was used, followed by 6 hours of basal conditions. 
The results shown in FIG. 8 indicate that insulin secretion 
from the multiple-copy systems can follow the square waves 
of DOX induction. On the other hand, the one-copy control 
failed to follow the square waves of DOX induction. These 
results indicate that placing I, 2 or 3 copies of the prepro-
insulin gene downstream of the stop codon all destabilize the 
preproinsulin mRNA, albeit to possibly different extents, 
and improve the dynamics of insulin secretion. 
<160> NUMBER OF SEQ ID NOS: 11 
<210> SEQ ID NO 1 
<211 > LENGTH: 13 7 
<212> TYPE: DNA 
SEQUENCE LISTING 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
15 
obtained and subsequently connected to the XbaI site at the 
3' end of preproinsulin gene in Vector F. 
Assays 
Transcription levels, secretion of insulin, and the dynam-
ics of insulin gene expression and insulin secretion were 
20 evaluated as described in Examples 1-4. 
Results 
The down-regulation in the secretion of insulin was 
examined using a construct that included a preproinsulin 
gene operatively linked to a luciferase cDNA in an attempt 
25 to generate nonsense-mediated mRNA decay. In comparison 
to constructs containing multiple copies of the preproinsulin 
gene, this approach also creates a distance between the 
translation stop codon of the preproinsulin gene and the 
polyadenylation signal. The size of luciferase gene is 1650 
30 bp, in comparison to the preproinsulin gene which is 360 bp 
in length. FIG. 9 shows the down-regulation of preproinsu-
lin-luciferase hybrid mRNA (FIG. 9A) and insulin secretion 
rate (FIG. 9B) were similar to the dynamics of the three-
copy system as shown in FIGS. 3A and 3B (filled squares). 
35 This result demonstrates that the fast down-regulation of 
insulin secretion is not limited to systems containing mul-
tiple-copies of the preproinsulin gene. When the preproin-
sulin gene was connected with a different DNA sequence 
such as the luciferase gene, a faster down-regulation of 
40 insulin expression was observed compared to the one-copy 
insulin control construct as shown in FIGS. 3A and 3B (open 
circles). 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
chimeric intron sequence 
<400> SEQUENCE: 1 
caggtaagta tcaaggttac aagacaggtt taaggagacc aatagaaact gggcttgtcg 60 
agacagagaa gactcttgcg tttctgatag gcacctattg gtcttactga catccacttt 120 
gcctttctct ccacagg 137 
<210> SEQ ID NO 2 
<211> LENGTH: 333 
<212> TYPE: DNA 
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-continued 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 2 
atggccctgt ggatgcgcct cctgcccctg ctggcgctgc tggccctctg gggacctgac 60 
ccagccgcag cctttgtgaa ccaacacctg tgcggatccg acctggtgga agctctctac 120 
ctagtgtgcg gggaacgagg cttcttctac acacccagga ccaagcggga ggcagaggac 180 
ctgcaggtgg ggcaggtgga gctgggcggg ggccctggtg caggcagcct gcagcccttg 240 
gccctggagg gatcccggca gaagcgtggc attgtggaac aatgctgtac cagcatctgc 300 
tccctctacc agctggagaa ctactgcaac tag 333 
<210> SEQ ID NO 3 
<211> LENGTH: 1080 
<212> TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 
ctagagtcga cctgcagaag cttaccatgg ccctgtggat gcgcctcctg cccctgctgg 60 
cgctgctggc cctctgggga cctgacccag ccgcagcctt tgtgaaccaa cacctgtgcg 120 
gatccgacct ggtggaagct ctctacctag tgtgcgggga acgaggcttc ttctacacac 180 
ccaggaccaa gcgggaggca gaggacctgc aggtggggca ggtggagctg ggcgggggcc 240 
ctggtgcagg cagcctgcag cccttggccc tggagggatc ccggcagaag cgtggcattg 300 
tggaacaatg ctgtaccagc atctgctccc tctaccagct ggagaactac tgcaactagt 360 
ctagagtcga cctgcagaag cttaccatgg ccctgtggat gcgcctcctg cccctgctgg 420 
cgctgctggc cctctgggga cctgacccag ccgcagcctt tgtgaaccaa cacctgtgcg 480 
gatccgacct ggtggaagct ctctacctag tgtgcgggga acgaggcttc ttctacacac 540 
ccaggaccaa gcgggaggca gaggacctgc aggtggggca ggtggagctg ggcgggggcc 600 
ctggtgcagg cagcctgcag cccttggccc tggagggatc ccggcagaag cgtggcattg 660 
tggaacaatg ctgtaccagc atctgctccc tctaccagct ggagaactac tgcaactaga 720 
gtcgacctgc agaagcttac catggccctg tggatgcgcc tcctgcccct gctggcgctg 780 
ctggccctct ggggacctga cccagccgca gcctttgtga accaacacct gtgcggatcc 840 
gacctggtgg aagctctcta cctagtgtgc ggggaacgag gcttcttcta cacacccagg 900 
accaagcggg aggcagagga cctgcaggtg gggcaggtgg agctgggcgg gggccctggt 960 
gcaggcagcc tgcagccctt ggccctggag ggatcccggc agaagcgtgg cattgtggaa 1020 
caatgctgta ccagcatctg ctccctctac cagctggaga actactgcaa ctagtctaga 1080 
<210> SEQ ID NO 4 
<211> LENGTH: 1217 
<212> TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 
caggtaagta tcaaggttac aagacaggtt taaggagacc aatagaaact gggcttgtcg 60 
agacagagaa gactcttgcg tttctgatag gcacctattg gtcttactga catccacttt 120 
gcctttctct ccacaggcta gagtcgacct gcagaagctt accatggccc tgtggatgcg 180 
cctcctgccc ctgctggcgc tgctggccct ctggggacct gacccagccg cagcctttgt 240 
gaaccaacac ctgtgcggat ccgacctggt ggaagctctc tacctagtgt gcggggaacg 300 
aggcttcttc tacacaccca ggaccaagcg ggaggcagag gacctgcagg tggggcaggt 360 
ggagctgggc gggggccctg 
gcagaagcgt ggcattgtgg 
gaactactgc aactagtcta 
cctcctgccc ctgctggcgc 
gaaccaacac ctgtgcggat 
aggcttcttc tacacaccca 
ggagctgggc gggggccctg 
gcagaagcgt ggcattgtgg 
gaactactgc aactagagtc 
tgcccctgct ggcgctgctg 
aacacctgtg cggatccgac 
tcttctacac acccaggacc 
tgggcggggg ccctggtgca 
agcgtggcat tgtggaacaa 
actgcaacta gtctaga 
<210> SEQ ID NO 5 
<211> LENGTH: 110 
<212> TYPE: PRT 
37 
gtgcaggcag 
aacaatgctg 
gagtcgacct 
tgctggccct 
ccgacctggt 
ggaccaagcg 
gtgcaggcag 
aacaatgctg 
gacctgcaga 
gccctctggg 
ctggtggaag 
aagcgggagg 
ggcagcctgc 
tgctgtacca 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 5 
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-continued 
cctgcagccc ttggccctgg agggatcccg 
tac cage ate tgctccctct accagctgga 
gcagaagctt accatggccc tgtggatgcg 
ctggggacct gacccagccg cagcctttgt 
ggaagctctc tacctagtgt gcggggaacg 
ggaggcagag gacctgcagg tggggcaggt 
cctgcagccc ttggccctgg agggatcccg 
tac cage ate tgctccctct accagctgga 
agcttaccat ggccctgtgg atgcgcctcc 
gacctgaccc agccgcagcc tttgtgaacc 
ctctctacct agtgtgcggg gaacgaggct 
cagaggacct gcaggtgggg caggtggagc 
agcccttggc cctggaggga tcccggcaga 
gcatctgctc cctctaccag ctggagaact 
Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu 
1 5 10 15 
Trp Gly Pro Asp Pro Ala Ala Ala Phe Val Asn Gln His Leu Cys Gly 
20 25 30 
Ser Asp Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe 
35 40 45 
Phe Tyr Thr Pro Arg Thr Lys Arg Glu Ala Glu Asp Leu Gln Val Gly 
50 55 60 
Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu 
65 70 75 80 
Ala Leu Glu Gly Ser Arg Gln Lys Arg Gly Ile Val Glu Gln Cys Cys 
85 90 95 
Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn 
100 105 110 
<210> SEQ ID NO 6 
<211> LENGTH: 30 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Probe 
<400> SEQUENCE: 6 
tccgacctgg tggaagctct ctacctagtg 
<210> SEQ ID NO 7 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer 
38 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1217 
30 
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-continued 
<400> SEQUENCE: 7 
tttgtgaacc aacacctgtg c 
<210> SEQ ID NO 8 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
21 
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer 
<400> SEQUENCE: 8 
gggtgtgtag aagaagcctc gtt 
<210> SEQ ID NO 9 
<211> LENGTH: 28 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
23 
<223> OTHER INFORMATION: Description of Artificial Sequence: Probe 
<400> SEQUENCE: 9 
cccgtaaact cgcccagaag ctaggtgt 
<210> SEQ ID NO 10 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
28 
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer 
<400> SEQUENCE: 10 
ggtcggaatc gaaggtttaa ca 
<210> SEQ ID NO 11 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
22 
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer 
<400> SEQUENCE: 11 
tgccaataca atgtaggctg ct 
We claim: 
1. A nucleic acid construct that produces a nonsense 
mediated mRNA transcript encoding a transcriptionally 
regulated insulin protein, wherein the nonsense mediated 
mRNA transcript has a shorter half-life than an mRNA 
encoding the transcriptionally regulated insulin protein that 
22 
4. The nucleic acid construct of claim 3, wherein the stop 
codon is located approximately 350-1650 nucleotides 
50 upstream of the polyadenylation sequence. 
5. The nucleic acid construct of claim 3, wherein the stop 
codon is located approximately 600-800 nucleotides 
upstream of the polyadenylation sequence. 
is not nonsense mediated, and wherein said nucleic acid 
construct comprises a nucleic acid sequence of SEQ ID 55 
N0:2, SEQ ID N0:3, or SEQ ID N0:4. 
6. The nucleic acid construct of claim 3, wherein the stop 
codon is located approximately 700 nucleotides upstream of 
the polyadenylation sequence. 
2. The nucleic acid construct of claim 1, wherein the 
nonsense mediated mRNA transcript comprises a sequence 
for a premature termination signal. 
3. The nucleic acid construct of claim 2, wherein the 
sequence for the premature termination signal comprises a 
stop codon in the portion of the mRNA transcript encoding 
the transcriptionally regulated protein, a polyadenylation 
sequence and a supplementary nucleic acid sequence 
inserted between the stop codon and the polyadenylation 
sequence. 
60 
7. The nucleic acid construct of claim 3, wherein the 
supplementary nucleic acid sequence comprises at least one 
copy of a preproinsulin polynucleotide. 
8. The nucleic acid construct of claim 3, wherein the 
supplementary nucleic acid sequence comprises approxi-
mately two copies of a preproinsulin polynucleotide. 
9. The nucleic acid construct of claim 1, comprising the 
65 nucleic acid sequence of SEQ ID N0:2. 
10. The nucleic acid construct of claim 1, comprising the 
nucleic acid sequence of SEQ ID N0:3. 
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11. The nucleic acid construct of claim 1, comprising the 
nucleic acid sequence of SEQ ID N0:4. 
12. An isolated, mammalian non-~ cell comprising a 
heterologous nucleic acid construct which produces a non-
sense mediated mRNA transcript encoding a transcription-
ally regulated insulin protein, wherein said heterologous 
nucleic acid construct comprises a nucleic acid sequence of 
SEQ ID N0:2, SEQ ID N0:3, or SEQ ID N0:4, and wherein 
the transcriptionally regulated protein is secreted by the cell 
and the nonsense mediated mRNA insulin transcript has a 10 
shorter half-life than an mRNA encoding the transcription-
ally regulated insulin protein that is not nonsense mediated. 
42 
transcript has a shorter half-life than an mRNA encod-
ing the transcriptionally regulated insulin protein that is 
not nonsense mediated; 
to thereby down-regulate secretion of the insulin protein. 
28. The method of claim 27, wherein the transcriptionally 
regulated protein is human insulin protein. 
29. The method of claim 27, wherein the heterologous 
nucleic acid construct comprises a sequence of SEQ ID 
N0:2 that encodes preproinsulin. 
30. The method of claim 27, wherein the nonsense medi-
ated mRNA transcript comprises a sequence for a premature 
termination signal. 
31. The method of claim 30, wherein the sequence for the 13. The cell of claim 12, wherein the nonsense mediated 
mRNA transcript comprises a sequence for a premature 
termination signal. 
14. The cell of claim 13, wherein the sequence for the 
premature termination signal comprises a stop codon in the 
portion of the mRNA transcript encoding the transcription-
ally regulated insulin protein, a polyadenylation sequence 
and a supplementary nucleic acid sequence inserted between 
the stop codon and the polyadenylation sequence. 
15 
premature termination signal comprises a stop codon of the 
mRNA transcript encoding the transcriptionally regulated 
insulin protein, a polyadenylation sequence and a supple-
mentary nucleic acid sequence inserted between the stop 
codon and the polyadenylation sequence. 
20 32. The method of claim 31, wherein the stop codon is 
located approximately 350-1650 nucleotides upstream of the 
polyadenylation sequence. 
15. The cell of claim 12, wherein the heterologous nucleic 
acid construct comprises the nucleic acid sequence of SEQ 
ID N0:2. 
16. The cell of claim 12, wherein the heterologous nucleic 25 
acid construct comprises the nucleic acid sequence of SEQ 
ID N0:3. 
33. The method of claim 31, wherein the stop codon is 
located approximately 600-800 nucleotides upstream of the 
polyadenylation sequence. 
34. The method of claim 31, wherein the stop codon is 
located approximately 700 nucleotides upstream of the 
polyadenylation sequence. 17. The cell of claim 12, wherein the heterologous nucleic 
acid construct comprises the nucleic acid sequence of SEQ 
ID N0:4. 
18. The cell of claim 14, wherein the stop codon is located 
approximately 350-1650 nucleotides upstream of the poly-
adenylation sequence. 
35. The method of claim 31, wherein the supplementary 
30 nucleic acid sequence comprises one or more preproinsulin 
protein coding sequences. 
19. The cell of claim 14, wherein the stop codon is located 
approximately 600-800 nucleotides upstream of the poly- 35 
adenylation sequence. 
36. The method of claim 27, wherein the cell is selected 
from the group consisting of an animal cell, a plant cell, a 
bacterial cell, a protozoa! cell, or a fungal cell. 
37. The method of claim 27, wherein the cell is an animal 
cell. 
38. The method of claim 27, wherein the cell is a human 
cell. 
20. The cell of claim 14, wherein the stop codon is located 
approximately 700 nucleotides upstream of the polyadeny-
lation sequence. 
21. The cell of claim 14, wherein the supplementary 
nucleic acid sequence comprises at least one copy of a 
preproinsulin polynucleotide. 
39. The method of claim 27, wherein the cell is a hepatic 
40 cell. 
22. The cell of claim 14, wherein the supplementary 
nucleic acid sequence comprises two copies of a preproin-
45 
sulin polynucleotide. 
23. The cell of claim 12, wherein the cell is a human cell. 
24. The cell of claim 12, wherein the cell is a hepatic cell. 
25. A method of treating a patient in need thereof, 
comprising administering to the patient a therapeutically 50 
effective amount of the cell of claim 12. 
26. The method of claim 25, wherein the disease is 
diabetes. 
40. The method of claim 27, wherein the cell is a non-~ 
cell. 
41. A cell produced using the method of claim 27. 
42. A method of treating a patient in need thereof, 
comprising administering to the patient a therapeutically 
effective amount of the cell of claim 41. 
43. The method of claim 42, wherein the patient has 
diabetes. 
44. A method of modulating the secretion dynamics of 
insulin by promoting degradation of preproinsulin mRNA, 
comprising introducing a heterologous nucleic acid into a 
non-~ cell, wherein the heterologous nucleic acid comprises 
a preproinsulin-encoding polynucleotide of SEQ ID N0:2, 27. A method for down-regulating secretion of a tran-
scriptionally regulated insulin protein comprising: 
a) introducing a heterologous nucleic acid construct into 
a cell, wherein said heterologous nucleic acid construct 
comprises a nucleic acid sequence of SEQ ID N0:2, 
SEQ ID N0:3, or SEQ ID N0:4, and wherein the 
heterologous nucleic acid construct transcribes a non-
sense mediated mRNA transcript which encodes the 
transcriptionally regulated protein; and 
55 SEQ ID N0:3, or SEQ ID N0:4 operatively linked to a 
promoter, and transcribes a nonsense mediated mRNA tran-
script which encodes the transcriptionally regulated insulin 
protein, wherein the nonsense mediated mRNA transcript 
comprises a sequence for a premature termination signal, 
60 and wherein the nonsense mediated mRNA transcript has a 
shorter half life than a mRNA encoding the transcriptionally 
regulated insulin protein that is not nonsense mediated, 
thereby modulating the secretion dynamics of insulin by b) expressing the heterologous nucleic acid construct to 
produce the nonsense mediated mRNA transcript 
encoding the transcriptionally regulated insulin protein, 65 
such that the transcriptionally regulated protein is 
secreted by the cell and the nonsense mediated mRNA 
promoting degradation of preproinsulin mRNA. 
45. The method of claim 44, wherein the sequence for the 
premature termination signal comprises a stop codon in the 
preproinsulin-encoding polynucleotide, a polyadenylation 
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sequence and a supplementary nucleic acid sequence 
inserted between the stop codon and the polyadenylation 
sequence. 
46. The method of claim 45, wherein the stop codon is 
located approximately 350-1650 nucleotides upstream of the 5 
polyadenylation sequence. 
47. The method of claim 45, wherein the stop codon is 
located approximately 600-800 nucleotides upstream of the 
polyadenylation sequence. 
48. The method of claim 45, wherein the stop codon is 10 
located approximately 700 nucleotides upstream of the 
polyadenylation sequence. 
49. The method of claim 45, wherein the supplementary 
nucleic acid sequence comprises at least one copy of a 
preproinsulin polynucleotide. 
44 
50. The method of claim 45, wherein the supplementary 
nucleic acid sequence comprises two copies of a preproin-
sulin polynucleotide. 
51. The method of claim 44, wherein the non-~ cell is a 
human cell. 
52. The method of claim 44, wherein the non-~ cell is a 
hepatic cell. 
53. A cell produced using the method of claim 44. 
54. A method of treating a patient in need thereof com-
prising administering to the patient a therapeutically effec-
tive amount of the cell of claim 53. 
55. The method of claim 54, wherein the disease is 
diabetes. 
* * * * * 
